Gene symbol   |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
1500003O 03Rik | |
NM_019769 |
RIKEN cDNA 1500003O03 gene (1500003O03Rik), mRNA [NM_019769] |
KLA | .92 |
.89 |
.89 |
.86 |
.85 |
.92 |
1.08 |
| ATP | 1.01 |
1.16 |
1.16 |
1.53 |
1.70 |
3.33 |
2.09 |
| KLA/ATP | .89 |
.97 |
.93 |
1.17 |
1.19 |
2.86 |
2.57 |
|
2010110P 09Rik | |
NM_027363 |
RIKEN cDNA 2010110P09 gene (2010110P09Rik), mRNA [NM_027363] |
KLA | .99 |
.98 |
1.02 |
.99 |
.94 |
1.01 |
1.01 |
| ATP | 1.04 |
1.05 |
.97 |
1.05 |
.95 |
.98 |
.95 |
| KLA/ATP | .93 |
1.00 |
1.02 |
.97 |
1.01 |
.96 |
.97 |
|
AK036998
| |
AK036998 |
adult female vagina cDNA, RIKEN full-length enriched library, clone:9930034M05 product:unclassifiable, full insert sequence. [AK036998] |
KLA | 1.43 |
1.09 |
.89 |
.79 |
.96 |
.97 |
.71 |
| ATP | 1.04 |
1.04 |
.71 |
.64 |
.90 |
.82 |
.82 |
| KLA/ATP | 1.34 |
1.23 |
1.01 |
.89 |
1.10 |
.82 |
.75 |
|
AK050363
| |
AK050363 |
adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730040N22 product:unclassifiable, full insert sequence. [AK050363] |
KLA | 1.00 |
.98 |
1.02 |
1.02 |
1.02 |
.92 |
.96 |
| ATP | .98 |
1.03 |
.93 |
.98 |
.96 |
1.02 |
.99 |
| KLA/ATP | 1.03 |
.96 |
.96 |
.95 |
1.02 |
.93 |
1.04 |
|
Akt1 | |
NM_009652 |
thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] |
KLA | .80 |
.80 |
.75 |
.75 |
.71 |
.70 |
.82 |
| ATP | 1.00 |
1.02 |
.76 |
.85 |
.76 |
.68 |
.84 |
| KLA/ATP | .82 |
.80 |
.64 |
.68 |
.67 |
.61 |
.72 |
|
Akt2 | |
NM_007434 |
thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] |
KLA | 1.45 |
1.49 |
1.81 |
1.61 |
1.83 |
1.17 |
.92 |
| ATP | 1.12 |
1.12 |
1.00 |
1.28 |
1.20 |
.94 |
1.06 |
| KLA/ATP | 1.48 |
1.70 |
1.69 |
1.58 |
1.57 |
1.32 |
1.27 |
|
Akt3 | |
NM_011785 |
thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] |
KLA | 3.42 |
3.45 |
5.31 |
5.16 |
4.65 |
3.80 |
2.12 |
| ATP | 1.12 |
1.22 |
1.10 |
1.37 |
1.02 |
1.11 |
1.56 |
| KLA/ATP | 3.72 |
4.17 |
4.62 |
4.64 |
2.74 |
2.05 |
3.82 |
|
Arrb1 | |
NM_177231 |
arrestin, beta 1 (Arrb1), transcript variant a, mRNA [NM_177231] |
KLA | .41 |
.42 |
.32 |
.32 |
.31 |
.56 |
.80 |
| ATP | .97 |
.86 |
.81 |
.62 |
.47 |
.59 |
1.16 |
| KLA/ATP | .43 |
.37 |
.38 |
.36 |
.35 |
.35 |
.89 |
|
Atf2 | |
AK047405 |
10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:B930056P03 product:activating transcription factor 2, full insert sequence. [AK047405] |
KLA | 1.01 |
1.00 |
1.02 |
1.04 |
1.03 |
1.03 |
1.00 |
| ATP | .99 |
1.00 |
.95 |
1.01 |
1.04 |
.98 |
1.03 |
| KLA/ATP | 1.07 |
1.00 |
.98 |
.99 |
1.00 |
1.03 |
.93 |
|
Atf2 | |
NM_001025093 |
activating transcription factor 2 (Atf2), transcript variant 1, mRNA [NM_001025093] |
KLA | 1.35 |
1.30 |
1.32 |
1.31 |
1.37 |
1.09 |
1.20 |
| ATP | 1.15 |
1.17 |
.99 |
1.11 |
1.22 |
1.39 |
1.28 |
| KLA/ATP | 1.38 |
1.42 |
1.21 |
1.28 |
1.17 |
1.33 |
1.69 |
|
Atf4 | |
NM_009716 |
activating transcription factor 4 (Atf4), mRNA [NM_009716] |
KLA | .91 |
1.06 |
1.13 |
1.31 |
1.92 |
2.59 |
3.01 |
| ATP | 1.05 |
1.14 |
1.34 |
2.88 |
4.84 |
2.36 |
2.56 |
| KLA/ATP | 1.14 |
1.08 |
1.17 |
2.40 |
3.72 |
3.54 |
3.62 |
|
B230120H 23Rik | |
NM_023057 |
RIKEN cDNA B230120H23 gene (B230120H23Rik), transcript variant 1, mRNA [NM_023057] |
KLA | 1.35 |
1.36 |
1.17 |
.91 |
.69 |
.43 |
.56 |
| ATP | 1.01 |
1.12 |
.87 |
1.32 |
1.71 |
1.48 |
.63 |
| KLA/ATP | 1.37 |
1.46 |
.95 |
1.14 |
1.07 |
1.22 |
.78 |
|
B230120H 23Rik | |
NM_178084 |
RIKEN cDNA B230120H23 gene (B230120H23Rik), transcript variant 2, mRNA [NM_178084] |
KLA | 1.08 |
1.07 |
1.06 |
1.00 |
.87 |
.62 |
.68 |
| ATP | 1.11 |
1.24 |
1.41 |
1.31 |
1.49 |
1.04 |
.79 |
| KLA/ATP | 1.13 |
1.24 |
1.17 |
1.07 |
1.04 |
.89 |
.85 |
|
BG242006
| |
BG242006 |
gb|602354740F1 NCI_CGAP_Mam1 Mus musculus cDNA clone IMAGE:4483064 5. [BG242006] |
KLA | 2.25 |
2.23 |
2.26 |
2.70 |
2.56 |
2.67 |
1.45 |
| ATP | .92 |
.87 |
1.11 |
.97 |
.99 |
.97 |
.72 |
| KLA/ATP | 1.91 |
2.04 |
2.51 |
2.08 |
1.99 |
1.15 |
.67 |
|
Bdnf | |
NM_007540 |
brain derived neurotrophic factor (Bdnf), transcript variant 1, mRNA [NM_007540] |
KLA | 1.00 |
1.01 |
1.01 |
1.01 |
1.01 |
1.00 |
.99 |
| ATP | 1.00 |
1.00 |
1.00 |
1.01 |
.99 |
.99 |
1.01 |
| KLA/ATP | 1.00 |
1.01 |
1.01 |
1.02 |
1.03 |
1.03 |
.98 |
|
Braf | |
NM_139294 |
Braf transforming gene (Braf), mRNA [NM_139294] |
KLA | 1.52 |
1.57 |
1.55 |
1.33 |
1.83 |
1.52 |
1.60 |
| ATP | 1.08 |
1.17 |
1.02 |
1.37 |
.95 |
1.15 |
.95 |
| KLA/ATP | 1.64 |
1.69 |
1.39 |
1.51 |
1.04 |
1.31 |
1.26 |
|
Cacna1a | |
NM_007578 |
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit (Cacna1a), mRNA [NM_007578] |
KLA | .71 |
.66 |
.61 |
.63 |
.60 |
.71 |
.72 |
| ATP | 1.07 |
1.04 |
.89 |
1.08 |
.71 |
.56 |
.75 |
| KLA/ATP | .71 |
.72 |
.85 |
.69 |
.64 |
.63 |
.68 |
|
Cacna1b | |
U04999 |
N-type calcium channel alpha1 subunit mRNA, complete cds [U04999] |
KLA | .94 |
.94 |
.95 |
.88 |
1.09 |
.85 |
.92 |
| ATP | 1.06 |
1.17 |
1.00 |
1.24 |
1.59 |
1.15 |
1.17 |
| KLA/ATP | .91 |
.91 |
.95 |
.95 |
.90 |
.97 |
1.01 |
|
Cacna1d | |
NM_001083616 |
calcium channel, voltage-dependent, L type, alpha 1D subunit (Cacna1d), transcript variant 2, mRNA [NM_001083616] |
KLA | 1.57 |
1.58 |
2.50 |
3.62 |
4.55 |
2.93 |
.99 |
| ATP | 1.12 |
.99 |
.97 |
.94 |
.75 |
1.71 |
1.48 |
| KLA/ATP | 1.47 |
1.51 |
1.82 |
1.56 |
1.67 |
2.93 |
4.60 |
|
Cacna1d | |
NM_028981 |
calcium channel, voltage-dependent, L type, alpha 1D subunit (Cacna1d), transcript variant 1, mRNA [NM_028981] |
KLA | 1.20 |
1.26 |
1.43 |
1.62 |
2.07 |
1.66 |
1.00 |
| ATP | 1.03 |
1.03 |
.97 |
.97 |
.93 |
1.20 |
1.26 |
| KLA/ATP | 1.16 |
1.12 |
1.10 |
1.14 |
1.08 |
1.44 |
2.56 |
|
Cacna1e | |
NM_009782 |
calcium channel, voltage-dependent, R type, alpha 1E subunit (Cacna1e), mRNA [NM_009782] |
KLA | 1.01 |
.96 |
1.00 |
1.00 |
1.02 |
.99 |
1.04 |
| ATP | 1.03 |
.96 |
.95 |
1.01 |
1.02 |
1.02 |
1.00 |
| KLA/ATP | 1.01 |
1.01 |
1.00 |
1.04 |
.97 |
1.03 |
1.00 |
|
Cacna1f | |
NM_019582 |
calcium channel, voltage-dependent, alpha 1F subunit (Cacna1f), mRNA [NM_019582] |
KLA | 1.03 |
.98 |
1.05 |
1.06 |
1.00 |
1.02 |
1.01 |
| ATP | 1.05 |
1.05 |
.95 |
.98 |
.97 |
.96 |
1.01 |
| KLA/ATP | 1.01 |
1.03 |
.94 |
1.01 |
1.01 |
1.00 |
.99 |
|
Cacna1g | |
NM_009783 |
calcium channel, voltage-dependent, T type, alpha 1G subunit (Cacna1g), transcript variant 1, mRNA [NM_009783] |
KLA | .98 |
.96 |
.95 |
1.02 |
.99 |
1.03 |
1.01 |
| ATP | .95 |
.98 |
1.03 |
1.00 |
1.01 |
1.01 |
1.01 |
| KLA/ATP | 1.00 |
.97 |
.93 |
.99 |
.94 |
1.00 |
1.06 |
|
Cacna1h | |
NM_021415 |
calcium channel, voltage-dependent, T type, alpha 1H subunit (Cacna1h), mRNA [NM_021415] |
KLA | 1.07 |
1.00 |
1.04 |
1.01 |
1.02 |
.98 |
1.06 |
| ATP | .97 |
.96 |
1.05 |
1.00 |
1.00 |
.96 |
.99 |
| KLA/ATP | 1.00 |
.99 |
.96 |
.98 |
.96 |
.97 |
.92 |
|
Cacna1i | |
NM_001044308 |
calcium channel, voltage-dependent, alpha 1I subunit (Cacna1i), mRNA [NM_001044308] |
KLA | 1.02 |
.96 |
1.01 |
.98 |
1.00 |
1.05 |
.90 |
| ATP | .98 |
1.00 |
1.05 |
.98 |
1.04 |
.95 |
.99 |
| KLA/ATP | .97 |
.94 |
1.02 |
1.03 |
1.03 |
1.03 |
1.01 |
|
Cacna1s | |
NM_001081023 |
calcium channel, voltage-dependent, L type, alpha 1S subunit (Cacna1s), mRNA [NM_001081023] |
KLA | 1.03 |
1.01 |
.96 |
1.06 |
1.00 |
1.00 |
1.05 |
| ATP | 1.01 |
.98 |
1.02 |
1.02 |
1.05 |
1.07 |
1.05 |
| KLA/ATP | .99 |
1.05 |
1.02 |
1.05 |
1.03 |
1.05 |
1.00 |
|
Cacna2d1
| |
AK046959 |
10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:B930007O16 product:calcium channel, voltage-dependent, alpha2/delta subunit 1, full insert sequence. [AK046959] |
KLA | 1.04 |
1.01 |
.94 |
.95 |
1.04 |
1.05 |
1.05 |
| ATP | 1.06 |
.98 |
.99 |
1.04 |
1.02 |
1.00 |
1.05 |
| KLA/ATP | 1.04 |
1.01 |
.99 |
1.04 |
.99 |
1.01 |
.99 |
|
Cacna2d1
| |
NM_009784 |
calcium channel, voltage-dependent, alpha2/delta subunit 1 (Cacna2d1), transcript variant e, mRNA [NM_009784] |
KLA | 1.02 |
1.02 |
1.02 |
1.00 |
1.03 |
1.01 |
1.02 |
| ATP | .99 |
.97 |
1.07 |
1.01 |
.99 |
.97 |
1.00 |
| KLA/ATP | 1.03 |
.99 |
1.01 |
1.04 |
1.03 |
1.01 |
.92 |
|
Cacna2d2
| |
NM_020263 |
calcium channel, voltage-dependent, alpha 2/delta subunit 2 (Cacna2d2), mRNA [NM_020263] |
KLA | 1.03 |
1.04 |
1.03 |
.99 |
1.03 |
.93 |
.93 |
| ATP | 1.01 |
1.06 |
1.06 |
1.15 |
1.03 |
.99 |
.93 |
| KLA/ATP | 1.04 |
1.01 |
1.10 |
1.13 |
1.11 |
.97 |
.89 |
|
Cacna2d3
| |
NM_009785 |
calcium channel, voltage-dependent, alpha2/delta subunit 3 (Cacna2d3), mRNA [NM_009785] |
KLA | 1.00 |
.98 |
1.07 |
.96 |
.99 |
.99 |
.99 |
| ATP | .99 |
.97 |
1.10 |
.99 |
1.00 |
.89 |
.97 |
| KLA/ATP | .95 |
1.04 |
1.00 |
.95 |
1.02 |
.99 |
.98 |
|
Cacna2d4
| |
AK030723 |
8 days embryo whole body cDNA, RIKEN full-length enriched library, clone:5730412N02 product:hypothetical von Willebrand factor type A domain containing protein, full insert sequence. [AK030723] |
KLA | .97 |
1.02 |
1.04 |
1.01 |
1.00 |
1.03 |
1.02 |
| ATP | 1.01 |
.93 |
1.03 |
1.01 |
.99 |
.99 |
1.01 |
| KLA/ATP | 1.03 |
.95 |
.87 |
.96 |
1.03 |
.97 |
1.05 |
|
Cacnb1 | |
NM_031173 |
calcium channel, voltage-dependent, beta 1 subunit (Cacnb1), transcript variant variant 1, mRNA [NM_031173] |
KLA | 1.35 |
1.26 |
1.13 |
1.51 |
1.54 |
1.69 |
2.10 |
| ATP | 1.01 |
1.09 |
1.16 |
1.23 |
1.39 |
1.61 |
1.34 |
| KLA/ATP | 1.20 |
1.34 |
1.81 |
1.43 |
1.62 |
1.50 |
2.03 |
|
Cacnb2 | |
AK143332 |
2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330008B16 product:calcium channel, voltage-dependent, beta 2 subunit, full insert sequence [AK143332] |
KLA | 1.18 |
1.19 |
1.17 |
1.05 |
1.03 |
1.03 |
1.03 |
| ATP | .97 |
.91 |
1.02 |
1.07 |
.95 |
1.07 |
1.03 |
| KLA/ATP | 1.20 |
1.29 |
1.16 |
1.09 |
1.02 |
1.05 |
1.03 |
|
Cacnb2 | |
NM_023116 |
calcium channel, voltage-dependent, beta 2 subunit (Cacnb2), mRNA [NM_023116] |
KLA | 1.23 |
1.15 |
1.47 |
1.25 |
1.02 |
1.02 |
1.05 |
| ATP | 1.00 |
1.01 |
.99 |
.99 |
1.02 |
1.01 |
1.01 |
| KLA/ATP | 1.21 |
1.27 |
1.12 |
1.24 |
.96 |
.98 |
1.02 |
|
Cacnb3 | |
NM_007581 |
calcium channel, voltage-dependent, beta 3 subunit (Cacnb3), transcript variant 1, mRNA [NM_007581] |
KLA | 5.88 |
5.27 |
7.39 |
5.78 |
4.94 |
2.13 |
1.26 |
| ATP | 1.03 |
1.02 |
1.22 |
1.37 |
2.49 |
2.75 |
1.61 |
| KLA/ATP | 5.92 |
6.99 |
6.43 |
6.99 |
5.42 |
3.70 |
2.61 |
|
Cacnb4 | |
NM_001037099 |
calcium channel, voltage-dependent, beta 4 subunit (Cacnb4), transcript variant 1, mRNA [NM_001037099] |
KLA | 1.07 |
1.11 |
1.17 |
1.11 |
1.15 |
1.13 |
1.07 |
| ATP | 1.00 |
1.00 |
1.03 |
1.06 |
1.21 |
1.17 |
1.50 |
| KLA/ATP | 1.13 |
1.12 |
1.15 |
1.16 |
1.35 |
1.69 |
1.32 |
|
Cacng1 | |
NM_007582 |
calcium channel, voltage-dependent, gamma subunit 1 (Cacng1), mRNA [NM_007582] |
KLA | .98 |
.93 |
.99 |
.99 |
.96 |
.99 |
1.04 |
| ATP | 1.07 |
1.40 |
2.33 |
2.01 |
1.57 |
1.10 |
1.08 |
| KLA/ATP | 1.02 |
.94 |
.98 |
1.16 |
1.07 |
.98 |
1.05 |
|
Cacng2 | |
AK047238 |
10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:B930041E13 product:hypothetical protein, full insert sequence [AK047238] |
KLA | 1.18 |
1.18 |
1.12 |
1.11 |
1.10 |
1.17 |
1.35 |
| ATP | 1.03 |
.98 |
1.09 |
1.04 |
1.07 |
1.06 |
1.00 |
| KLA/ATP | 1.15 |
1.15 |
1.25 |
1.15 |
1.12 |
1.07 |
1.19 |
|
Cacng2 | |
NM_007583 |
calcium channel, voltage-dependent, gamma subunit 2 (Cacng2), mRNA [NM_007583] |
KLA | 1.00 |
1.08 |
1.08 |
.95 |
1.07 |
1.09 |
1.03 |
| ATP | 1.04 |
1.05 |
1.05 |
1.04 |
1.00 |
1.02 |
.99 |
| KLA/ATP | 1.00 |
.98 |
1.02 |
1.09 |
1.06 |
1.07 |
1.03 |
|
Cacng3 | |
NM_019430 |
calcium channel, voltage-dependent, gamma subunit 3 (Cacng3), mRNA [NM_019430] |
KLA | 1.07 |
1.09 |
1.00 |
.97 |
1.01 |
.94 |
.89 |
| ATP | 1.06 |
1.11 |
1.07 |
1.00 |
.98 |
.99 |
.97 |
| KLA/ATP | 1.07 |
1.06 |
1.03 |
.94 |
1.00 |
.99 |
.95 |
|
Cacng4 | |
AJ272045 |
mRNA for calcium channel gamma 4 subunit (CACNG4 gene) [AJ272045] |
KLA | .99 |
.95 |
1.01 |
1.02 |
.98 |
1.09 |
.92 |
| ATP | .96 |
1.09 |
1.00 |
.95 |
.97 |
1.06 |
.95 |
| KLA/ATP | .97 |
1.01 |
1.04 |
.97 |
1.00 |
.96 |
.98 |
|
Cacng5 | |
NM_080644 |
calcium channel, voltage-dependent, gamma subunit 5 (Cacng5), mRNA [NM_080644] |
KLA | .98 |
.99 |
.91 |
.98 |
1.02 |
.98 |
.98 |
| ATP | .96 |
1.02 |
.99 |
.99 |
1.05 |
1.04 |
.95 |
| KLA/ATP | .95 |
1.01 |
1.07 |
.99 |
1.02 |
.95 |
.99 |
|
Cacng6 | |
NM_133183 |
calcium channel, voltage-dependent, gamma subunit 6 (Cacng6), mRNA [NM_133183] |
KLA | .95 |
.95 |
.94 |
1.03 |
.94 |
1.09 |
1.14 |
| ATP | 1.00 |
1.05 |
.95 |
1.05 |
.94 |
.93 |
.99 |
| KLA/ATP | 1.02 |
.98 |
.92 |
.97 |
1.02 |
.96 |
1.05 |
|
Cacng7 | |
NM_133189 |
calcium channel, voltage-dependent, gamma subunit 7 (Cacng7), mRNA [NM_133189] |
KLA | 1.01 |
1.04 |
.98 |
1.01 |
1.00 |
1.05 |
1.02 |
| ATP | 1.05 |
1.03 |
.99 |
1.00 |
.98 |
.95 |
.98 |
| KLA/ATP | 1.00 |
.98 |
1.07 |
.99 |
.97 |
1.03 |
1.01 |
|
Cacng8 | |
NM_133190 |
calcium channel, voltage-dependent, gamma subunit 8 (Cacng8), mRNA [NM_133190] |
KLA | 1.17 |
1.16 |
1.20 |
1.31 |
1.16 |
1.13 |
1.09 |
| ATP | .98 |
1.09 |
1.06 |
1.06 |
1.03 |
1.18 |
.99 |
| KLA/ATP | 1.27 |
1.35 |
1.29 |
1.09 |
1.04 |
1.06 |
1.19 |
|
Casp3 | |
NM_009810 |
caspase 3 (Casp3), mRNA [NM_009810] |
KLA | 1.66 |
1.94 |
2.47 |
2.61 |
3.01 |
2.96 |
1.44 |
| ATP | .90 |
.99 |
1.17 |
1.30 |
1.01 |
1.17 |
.86 |
| KLA/ATP | 1.55 |
1.87 |
2.40 |
2.35 |
2.27 |
2.84 |
2.52 |
|
Casp3 | |
U49929 |
ICE-like cysteine protease (Lice) mRNA, complete cds. [U49929] |
KLA | 1.71 |
1.87 |
2.69 |
3.11 |
3.64 |
3.42 |
1.52 |
| ATP | 1.04 |
1.07 |
1.16 |
1.34 |
.98 |
1.27 |
.86 |
| KLA/ATP | 1.80 |
1.96 |
2.46 |
2.91 |
2.50 |
3.24 |
3.10 |
|
Cd14 | |
NM_009841 |
CD14 antigen (Cd14), mRNA [NM_009841] |
KLA | 2.35 |
2.68 |
2.54 |
2.21 |
2.39 |
1.52 |
1.57 |
| ATP | 1.44 |
2.28 |
2.82 |
3.98 |
6.68 |
16.14 |
6.92 |
| KLA/ATP | 2.92 |
3.79 |
3.96 |
5.12 |
5.29 |
10.42 |
11.50 |
|
Cdc25b | |
NM_023117 |
cell division cycle 25 homolog B (S. pombe) (Cdc25b), transcript variant 1, mRNA [NM_023117] |
KLA | .38 |
.34 |
.33 |
.34 |
.30 |
.31 |
.26 |
| ATP | .98 |
1.04 |
1.01 |
.89 |
.67 |
.58 |
.39 |
| KLA/ATP | .36 |
.33 |
.37 |
.40 |
.51 |
.43 |
.32 |
|
Cdc42 | |
NM_009861 |
cell division cycle 42 homolog (S. cerevisiae) (Cdc42), mRNA [NM_009861] |
KLA | 1.04 |
1.01 |
1.02 |
1.04 |
1.12 |
1.21 |
1.12 |
| ATP | 1.07 |
1.10 |
1.04 |
1.06 |
1.02 |
.95 |
1.14 |
| KLA/ATP | .94 |
1.04 |
1.01 |
.97 |
.95 |
1.02 |
1.25 |
|
Chuk | |
NM_007700 |
conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] |
KLA | 1.32 |
1.42 |
1.41 |
1.17 |
1.32 |
1.22 |
1.40 |
| ATP | 1.22 |
1.30 |
1.18 |
.97 |
1.02 |
1.00 |
1.37 |
| KLA/ATP | 1.56 |
1.61 |
1.21 |
1.09 |
.83 |
.84 |
1.17 |
|
Crk | |
NM_133656 |
v-crk sarcoma virus CT10 oncogene homolog (avian) (Crk), mRNA [NM_133656] |
KLA | 1.29 |
1.32 |
1.41 |
1.38 |
1.75 |
1.59 |
1.52 |
| ATP | 1.08 |
1.17 |
1.01 |
.93 |
1.27 |
2.11 |
1.70 |
| KLA/ATP | 1.37 |
1.49 |
1.14 |
1.09 |
1.21 |
1.69 |
2.32 |
|
Crkl | |
NM_007764 |
v-crk sarcoma virus CT10 oncogene homolog (avian)-like (Crkl), mRNA [NM_007764] |
KLA | 1.85 |
1.97 |
2.08 |
1.73 |
1.66 |
1.64 |
1.36 |
| ATP | .97 |
.94 |
.78 |
.74 |
1.46 |
1.89 |
1.46 |
| KLA/ATP | 1.92 |
1.88 |
1.18 |
1.44 |
1.67 |
2.65 |
2.72 |
|
Daxx | |
NM_007829 |
Fas death domain-associated protein (Daxx), mRNA [NM_007829] |
KLA | 13.43 |
12.31 |
10.74 |
10.71 |
8.02 |
8.78 |
4.52 |
| ATP | .88 |
.79 |
.74 |
.47 |
1.05 |
5.31 |
2.46 |
| KLA/ATP | 11.40 |
11.89 |
13.01 |
10.51 |
12.32 |
11.59 |
9.74 |
|
Ddit3 | |
NM_007837 |
DNA-damage inducible transcript 3 (Ddit3), mRNA [NM_007837] |
KLA | .61 |
.59 |
.70 |
1.06 |
1.69 |
2.77 |
3.31 |
| ATP | .87 |
.65 |
.80 |
1.34 |
1.88 |
1.58 |
4.98 |
| KLA/ATP | .58 |
.51 |
.67 |
1.54 |
4.63 |
3.78 |
8.88 |
|
Dusp1 | |
NM_013642 |
dual specificity phosphatase 1 (Dusp1), mRNA [NM_013642] |
KLA | 4.56 |
3.88 |
6.42 |
8.88 |
7.87 |
4.61 |
3.97 |
| ATP | 4.35 |
6.31 |
15.22 |
22.62 |
6.79 |
7.21 |
2.84 |
| KLA/ATP | 5.44 |
7.70 |
16.61 |
23.52 |
9.62 |
11.17 |
12.72 |
|
Dusp10 | |
NM_022019 |
dual specificity phosphatase 10 (Dusp10), mRNA [NM_022019] |
KLA | 1.82 |
1.74 |
2.08 |
2.69 |
1.59 |
1.61 |
1.29 |
| ATP | .83 |
.87 |
1.73 |
4.48 |
11.77 |
9.59 |
2.67 |
| KLA/ATP | 1.53 |
1.59 |
2.07 |
4.99 |
10.11 |
14.05 |
6.90 |
|
Dusp14 | |
NM_019819 |
dual specificity phosphatase 14 (Dusp14), mRNA [NM_019819] |
KLA | 2.40 |
2.24 |
1.97 |
1.51 |
1.14 |
1.17 |
1.09 |
| ATP | .95 |
.98 |
1.81 |
6.09 |
11.10 |
11.62 |
4.14 |
| KLA/ATP | 2.35 |
2.46 |
1.86 |
3.07 |
4.69 |
10.09 |
10.64 |
|
Dusp16 | |
AF345951 |
map kinase phosphatase-M A1 isoform mRNA, complete cds. [AF345951] |
KLA | 5.69 |
5.60 |
5.88 |
5.66 |
4.01 |
2.22 |
2.25 |
| ATP | .96 |
.87 |
1.87 |
2.78 |
3.45 |
4.57 |
1.17 |
| KLA/ATP | 5.77 |
5.29 |
8.23 |
6.44 |
6.47 |
4.81 |
2.30 |
|
Dusp16 | |
NM_130447 |
dual specificity phosphatase 16 (Dusp16), transcript variant A1, mRNA [NM_130447] |
KLA | 2.73 |
2.96 |
3.39 |
2.65 |
2.55 |
1.58 |
1.60 |
| ATP | 1.02 |
1.07 |
1.49 |
1.70 |
1.62 |
2.35 |
1.25 |
| KLA/ATP | 3.05 |
3.22 |
3.07 |
3.12 |
2.11 |
2.77 |
2.28 |
|
Dusp2 | |
NM_010090 |
dual specificity phosphatase 2 (Dusp2), mRNA [NM_010090] |
KLA | 43.10 |
42.75 |
36.17 |
49.49 |
35.86 |
16.34 |
5.07 |
| ATP | .92 |
1.69 |
37.49 |
58.42 |
16.31 |
14.80 |
1.24 |
| KLA/ATP | 39.37 |
45.95 |
72.93 |
79.76 |
46.84 |
37.71 |
12.16 |
|
Dusp22 | |
NM_134068 |
dual specificity phosphatase 22 (Dusp22), transcript variant 2, mRNA [NM_134068] |
KLA | .79 |
.76 |
.76 |
.68 |
.58 |
.63 |
.60 |
| ATP | 1.18 |
1.16 |
1.08 |
.97 |
.71 |
.41 |
.50 |
| KLA/ATP | .79 |
.76 |
.78 |
.85 |
.57 |
.36 |
.54 |
|
Dusp3 | |
NM_028207 |
dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-related) (Dusp3), mRNA [NM_028207] |
KLA | .69 |
.71 |
.63 |
.72 |
.77 |
.83 |
.92 |
| ATP | 1.07 |
1.12 |
1.01 |
1.23 |
1.00 |
.85 |
2.22 |
| KLA/ATP | .70 |
.80 |
.65 |
.79 |
.77 |
.71 |
1.71 |
|
Dusp4 | |
AK012530 |
11 days embryo whole body cDNA, RIKEN full-length enriched library, clone:2700078F24 product:unclassifiable, full insert sequence [AK012530] |
KLA | .27 |
.25 |
.25 |
.23 |
.25 |
.24 |
.41 |
| ATP | 1.19 |
1.15 |
2.70 |
5.70 |
5.30 |
1.74 |
1.44 |
| KLA/ATP | .25 |
.29 |
1.36 |
4.31 |
3.60 |
.81 |
.92 |
|
Dusp4 | |
NM_176933 |
dual specificity phosphatase 4 (Dusp4), mRNA [NM_176933] |
KLA | .22 |
.22 |
.17 |
.26 |
.17 |
.24 |
.42 |
| ATP | 1.37 |
1.55 |
2.80 |
6.42 |
4.54 |
2.15 |
2.57 |
| KLA/ATP | .20 |
.28 |
.93 |
3.44 |
2.59 |
.72 |
1.83 |
|
Dusp6 | |
NM_026268 |
dual specificity phosphatase 6 (Dusp6), mRNA [NM_026268] |
KLA | .10 |
.08 |
.09 |
.08 |
.12 |
.25 |
.16 |
| ATP | 1.03 |
.73 |
.90 |
.43 |
.08 |
.40 |
.46 |
| KLA/ATP | .09 |
.07 |
.12 |
.13 |
.07 |
.11 |
.21 |
|
Dusp7 | |
NM_153459 |
dual specificity phosphatase 7 (Dusp7), mRNA [NM_153459] |
KLA | .19 |
.18 |
.28 |
.42 |
.50 |
.39 |
.38 |
| ATP | .98 |
.95 |
.88 |
.86 |
1.24 |
.39 |
.86 |
| KLA/ATP | .17 |
.17 |
.25 |
.31 |
.47 |
.42 |
.34 |
|
Dusp8 | |
NM_008748 |
dual specificity phosphatase 8 (Dusp8), mRNA [NM_008748] |
KLA | .80 |
.74 |
.62 |
.75 |
.65 |
.86 |
1.60 |
| ATP | .92 |
.91 |
2.28 |
4.12 |
1.71 |
.95 |
1.13 |
| KLA/ATP | .76 |
.67 |
.84 |
1.44 |
1.46 |
1.03 |
1.58 |
|
Dusp9 | |
NM_029352 |
dual specificity phosphatase 9 (Dusp9), mRNA [NM_029352] |
KLA | .84 |
.80 |
.83 |
.75 |
.67 |
.71 |
.85 |
| ATP | 1.01 |
.99 |
.89 |
.94 |
.94 |
.83 |
.81 |
| KLA/ATP | .85 |
.90 |
.87 |
.81 |
.67 |
.59 |
.81 |
|
Ecsit | |
NM_012029 |
ECSIT homolog (Drosophila) (Ecsit), mRNA [NM_012029] |
KLA | .63 |
.57 |
.52 |
.71 |
.75 |
.86 |
1.24 |
| ATP | .98 |
.86 |
.84 |
.81 |
.72 |
.88 |
1.18 |
| KLA/ATP | .63 |
.57 |
.68 |
.52 |
.52 |
.78 |
.78 |
|
Egf | |
NM_010113 |
epidermal growth factor (Egf), mRNA [NM_010113] |
KLA | .89 |
.90 |
.81 |
.83 |
.83 |
.86 |
.92 |
| ATP | 1.03 |
1.03 |
.95 |
.84 |
.67 |
.79 |
.88 |
| KLA/ATP | .86 |
.86 |
.77 |
.77 |
.69 |
.78 |
.83 |
|
Egfr | |
NM_007912 |
epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] |
KLA | 1.10 |
1.07 |
1.14 |
1.11 |
1.08 |
1.03 |
.90 |
| ATP | .99 |
1.00 |
1.04 |
.98 |
.97 |
1.15 |
1.14 |
| KLA/ATP | 1.07 |
1.10 |
1.16 |
1.08 |
1.01 |
.97 |
.94 |
|
Egfr | |
NM_207655 |
epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] |
KLA | 1.57 |
1.44 |
1.47 |
1.31 |
.96 |
.92 |
.76 |
| ATP | .97 |
.93 |
1.10 |
1.00 |
1.41 |
2.97 |
.86 |
| KLA/ATP | 1.44 |
1.50 |
1.61 |
1.30 |
1.14 |
1.21 |
.82 |
|
Elk1 | |
AK082260 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230030F12 product:ELK1, member of ETS oncogene family, full insert sequence. [AK082260] |
KLA | 1.02 |
1.01 |
1.01 |
.97 |
1.00 |
1.03 |
1.06 |
| ATP | 1.02 |
1.07 |
1.06 |
1.03 |
1.02 |
1.02 |
1.00 |
| KLA/ATP | 1.08 |
.99 |
.97 |
1.01 |
1.02 |
1.06 |
.95 |
|
Elk4 | |
AK037559 |
16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026I01 product:unclassifiable, full insert sequence. [AK037559] |
KLA | 1.04 |
.93 |
.96 |
.94 |
.99 |
1.06 |
.93 |
| ATP | .95 |
.98 |
.89 |
.92 |
.96 |
1.00 |
.96 |
| KLA/ATP | .94 |
.94 |
.99 |
.92 |
.93 |
.99 |
.96 |
|
Elk4 | |
NM_007923 |
ELK4, member of ETS oncogene family (Elk4), mRNA [NM_007923] |
KLA | .96 |
1.04 |
1.07 |
1.04 |
1.05 |
1.01 |
1.09 |
| ATP | .93 |
1.01 |
1.02 |
1.01 |
1.00 |
1.10 |
1.01 |
| KLA/ATP | .98 |
1.01 |
.94 |
1.02 |
1.03 |
1.04 |
1.04 |
|
Evi1 | |
BC076620 |
ecotropic viral integration site 1, mRNA (cDNA clone IMAGE:30645345), partial cds [BC076620] |
KLA | 1.04 |
.98 |
1.05 |
.96 |
1.09 |
1.04 |
.92 |
| ATP | .94 |
.96 |
1.11 |
1.00 |
1.03 |
1.08 |
1.14 |
| KLA/ATP | 1.00 |
.92 |
1.02 |
1.12 |
1.06 |
1.00 |
1.08 |
|
Evi1 | |
NM_007963 |
ecotropic viral integration site 1 (Evi1), mRNA [NM_007963] |
KLA | .93 |
.99 |
1.04 |
1.02 |
1.05 |
1.11 |
1.10 |
| ATP | .96 |
.96 |
.98 |
1.03 |
1.03 |
.85 |
1.02 |
| KLA/ATP | 1.04 |
.95 |
.97 |
1.01 |
1.10 |
1.09 |
.99 |
|
Fas | |
AK086933 |
0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030012O08 product:tumor necrosis factor receptor superfamily, member 6, full insert sequence. [AK086933] |
KLA | 6.31 |
6.56 |
6.33 |
6.70 |
4.93 |
3.74 |
2.48 |
| ATP | .95 |
1.04 |
1.33 |
1.55 |
1.85 |
6.00 |
2.77 |
| KLA/ATP | 5.67 |
7.16 |
7.71 |
7.73 |
6.02 |
5.79 |
7.85 |
|
Fas | |
NM_007987 |
Fas (TNF receptor superfamily member 6) (Fas), mRNA [NM_007987] |
KLA | 17.08 |
17.45 |
19.08 |
17.38 |
13.33 |
6.78 |
4.46 |
| ATP | .98 |
.96 |
1.64 |
3.05 |
5.58 |
12.91 |
1.89 |
| KLA/ATP | 16.57 |
17.25 |
26.06 |
23.57 |
22.03 |
16.74 |
13.29 |
|
Fasl | |
NM_010177 |
Fas ligand (TNF superfamily, member 6) (Fasl), mRNA [NM_010177] |
KLA | 1.03 |
1.01 |
1.03 |
1.02 |
1.01 |
1.01 |
1.00 |
| ATP | 1.00 |
.99 |
1.04 |
1.21 |
1.18 |
1.20 |
1.01 |
| KLA/ATP | 1.00 |
1.02 |
1.07 |
1.16 |
1.18 |
1.23 |
1.00 |
|
Fgf1 | |
NM_010197 |
fibroblast growth factor 1 (Fgf1), mRNA [NM_010197] |
KLA | 1.07 |
.99 |
.99 |
1.00 |
1.03 |
.97 |
.99 |
| ATP | 1.01 |
1.03 |
1.01 |
.95 |
.95 |
.98 |
.88 |
| KLA/ATP | 1.03 |
.99 |
.97 |
.99 |
.98 |
.94 |
1.01 |
|
Fgf10 | |
NM_008002 |
fibroblast growth factor 10 (Fgf10), mRNA [NM_008002] |
KLA | .99 |
.98 |
1.02 |
1.00 |
1.02 |
1.02 |
1.02 |
| ATP | 1.03 |
1.02 |
1.00 |
1.00 |
1.00 |
.99 |
.99 |
| KLA/ATP | 1.01 |
1.00 |
1.04 |
.99 |
1.00 |
1.02 |
1.01 |
|
Fgf11 | |
BC066859 |
fibroblast growth factor 11, mRNA (cDNA clone MGC:76712 IMAGE:30101881), complete cds [BC066859] |
KLA | .64 |
.61 |
.55 |
.58 |
.51 |
.48 |
.77 |
| ATP | 1.00 |
.96 |
.78 |
.78 |
.63 |
.44 |
.48 |
| KLA/ATP | .64 |
.63 |
.59 |
.56 |
.54 |
.42 |
.40 |
|
Fgf11 | |
NM_010198 |
fibroblast growth factor 11 (Fgf11), mRNA [NM_010198] |
KLA | .99 |
1.02 |
1.05 |
1.04 |
1.01 |
1.03 |
1.07 |
| ATP | .95 |
1.02 |
1.02 |
1.07 |
.98 |
1.01 |
1.07 |
| KLA/ATP | 1.01 |
1.01 |
1.08 |
.96 |
.97 |
.95 |
1.01 |
|
Fgf12 | |
NM_183064 |
fibroblast growth factor 12 (Fgf12), transcript variant 1, mRNA [NM_183064] |
KLA | .96 |
.97 |
1.05 |
.99 |
.97 |
1.01 |
1.01 |
| ATP | .93 |
.97 |
.97 |
.97 |
.99 |
.95 |
1.00 |
| KLA/ATP | 1.02 |
1.05 |
1.10 |
1.02 |
.95 |
1.01 |
.95 |
|
Fgf13 | |
NM_010200 |
fibroblast growth factor 13 (Fgf13), mRNA [NM_010200] |
KLA | .91 |
.92 |
.93 |
.84 |
.77 |
.66 |
.75 |
| ATP | 1.09 |
1.14 |
1.03 |
1.11 |
1.06 |
.68 |
.78 |
| KLA/ATP | .98 |
1.02 |
.86 |
.90 |
.78 |
.70 |
.79 |
|
Fgf14 | |
NM_010201 |
fibroblast growth factor 14 (Fgf14), transcript variant 1, mRNA [NM_010201] |
KLA | 1.04 |
1.05 |
1.02 |
1.04 |
1.03 |
1.05 |
1.03 |
| ATP | .99 |
1.08 |
1.04 |
1.00 |
.99 |
.98 |
1.04 |
| KLA/ATP | 1.00 |
1.00 |
1.08 |
1.00 |
1.04 |
1.01 |
1.03 |
|
Fgf14 | |
NM_207667 |
fibroblast growth factor 14 (Fgf14), transcript variant 2, mRNA [NM_207667] |
KLA | 1.04 |
1.01 |
.98 |
.93 |
.96 |
.96 |
.97 |
| ATP | 1.04 |
1.10 |
.94 |
.87 |
1.03 |
.99 |
.96 |
| KLA/ATP | .86 |
.94 |
1.03 |
.89 |
1.00 |
.90 |
1.03 |
|
Fgf15 | |
NM_008003 |
fibroblast growth factor 15 (Fgf15), mRNA [NM_008003] |
KLA | 1.00 |
1.00 |
.95 |
.98 |
.92 |
.96 |
1.01 |
| ATP | .99 |
1.01 |
.98 |
.98 |
.93 |
.95 |
.97 |
| KLA/ATP | .98 |
1.01 |
1.02 |
1.03 |
.97 |
.97 |
1.00 |
|
Fgf16 | |
NM_030614 |
fibroblast growth factor 16 (Fgf16), mRNA [NM_030614] |
KLA | 1.00 |
.97 |
.99 |
1.02 |
1.04 |
.97 |
.97 |
| ATP | 1.02 |
.99 |
.99 |
1.02 |
1.12 |
1.01 |
1.02 |
| KLA/ATP | 1.06 |
1.02 |
.99 |
1.01 |
1.00 |
1.10 |
1.03 |
|
Fgf17 | |
NM_008004 |
fibroblast growth factor 17 (Fgf17), mRNA [NM_008004] |
KLA | .97 |
1.03 |
.98 |
1.00 |
.97 |
.97 |
.86 |
| ATP | .99 |
.96 |
.99 |
.90 |
1.02 |
1.01 |
1.01 |
| KLA/ATP | .99 |
.91 |
1.08 |
.99 |
.99 |
.98 |
.99 |
|
Fgf18 | |
NM_008005 |
fibroblast growth factor 18 (Fgf18), mRNA [NM_008005] |
KLA | 1.17 |
1.18 |
1.16 |
1.12 |
1.03 |
1.13 |
1.04 |
| ATP | .96 |
.98 |
2.47 |
12.57 |
2.76 |
1.56 |
1.03 |
| KLA/ATP | 1.01 |
1.15 |
2.33 |
10.13 |
2.80 |
1.79 |
1.02 |
|
Fgf2 | |
NM_008006 |
fibroblast growth factor 2 (Fgf2), mRNA [NM_008006] |
KLA | 1.02 |
1.01 |
1.00 |
1.03 |
1.01 |
1.02 |
1.01 |
| ATP | .99 |
1.01 |
1.00 |
1.02 |
1.01 |
1.01 |
1.00 |
| KLA/ATP | 1.00 |
1.01 |
.98 |
1.01 |
1.02 |
1.03 |
1.01 |
|
Fgf20 | |
NM_030610 |
fibroblast growth factor 20 (Fgf20), mRNA [NM_030610] |
KLA | .97 |
1.08 |
.99 |
1.00 |
.97 |
1.00 |
.97 |
| ATP | 1.03 |
.95 |
.97 |
1.05 |
.98 |
.97 |
1.00 |
| KLA/ATP | .99 |
.99 |
1.06 |
1.04 |
1.02 |
.92 |
.96 |
|
Fgf21 | |
NM_020013 |
fibroblast growth factor 21 (Fgf21), mRNA [NM_020013] |
KLA | 1.02 |
1.03 |
.87 |
1.04 |
1.00 |
1.01 |
1.00 |
| ATP | 1.04 |
.97 |
1.00 |
1.02 |
.96 |
1.05 |
1.02 |
| KLA/ATP | 1.08 |
1.00 |
1.00 |
1.00 |
1.03 |
1.02 |
.99 |
|
Fgf22 | |
AK008922 |
adult male stomach cDNA, RIKEN full-length enriched library, clone:2210414E06 product:FIBROBLAST GROWTH FACTOR-22 PRECURSOR (FGF-22) homolog [Mus musculus], full insert sequence [AK008922] |
KLA | .90 |
.94 |
.95 |
1.04 |
1.03 |
.94 |
.97 |
| ATP | 1.04 |
1.01 |
.98 |
.93 |
.93 |
.95 |
.88 |
| KLA/ATP | .98 |
.97 |
.97 |
1.01 |
.95 |
.92 |
.95 |
|
Fgf22 | |
NM_023304 |
fibroblast growth factor 22 (Fgf22), mRNA [NM_023304] |
KLA | .99 |
.94 |
1.01 |
.95 |
.97 |
.89 |
.99 |
| ATP | 1.00 |
.95 |
1.00 |
.96 |
.97 |
.93 |
.98 |
| KLA/ATP | .91 |
1.00 |
1.01 |
.92 |
.95 |
.98 |
.97 |
|
Fgf23 | |
NM_022657 |
fibroblast growth factor 23 (Fgf23), mRNA [NM_022657] |
KLA | 1.32 |
1.39 |
1.27 |
1.22 |
1.07 |
1.03 |
1.14 |
| ATP | .95 |
1.00 |
1.05 |
1.07 |
1.05 |
1.02 |
.96 |
| KLA/ATP | 1.32 |
1.39 |
1.37 |
1.22 |
1.01 |
1.00 |
.90 |
|
Fgf3 | |
NM_008007 |
fibroblast growth factor 3 (Fgf3), mRNA [NM_008007] |
KLA | 1.03 |
1.05 |
1.00 |
.97 |
1.01 |
.98 |
.97 |
| ATP | 1.01 |
1.00 |
.97 |
1.03 |
.98 |
1.03 |
.97 |
| KLA/ATP | .98 |
1.00 |
1.01 |
1.03 |
1.03 |
1.00 |
.99 |
|
Fgf5 | |
NM_010203 |
fibroblast growth factor 5 (Fgf5), mRNA [NM_010203] |
KLA | 1.02 |
1.02 |
1.00 |
1.03 |
.97 |
1.05 |
.99 |
| ATP | 1.02 |
1.00 |
1.03 |
.97 |
.99 |
.97 |
1.04 |
| KLA/ATP | 1.05 |
.92 |
1.01 |
1.00 |
1.11 |
.96 |
.97 |
|
Fgf6 | |
M92416 |
fibroblast growth factor (Fgf6) mRNA, 3 end [M92416] |
KLA | 1.09 |
1.07 |
1.00 |
1.06 |
.97 |
1.01 |
.96 |
| ATP | 1.02 |
1.02 |
1.06 |
1.02 |
.93 |
.99 |
.98 |
| KLA/ATP | 1.04 |
.99 |
1.00 |
.99 |
1.00 |
1.00 |
1.03 |
|
Fgf6 | |
NM_010204 |
fibroblast growth factor 6 (Fgf6), mRNA [NM_010204] |
KLA | 1.00 |
.96 |
1.06 |
.96 |
.96 |
1.00 |
.91 |
| ATP | .94 |
1.00 |
.89 |
.95 |
1.01 |
.92 |
1.00 |
| KLA/ATP | .99 |
1.06 |
1.06 |
.86 |
1.00 |
.95 |
1.00 |
|
Fgf7 | |
NM_008008 |
fibroblast growth factor 7 (Fgf7), mRNA [NM_008008] |
KLA | 1.02 |
1.02 |
1.02 |
1.03 |
1.05 |
1.11 |
1.04 |
| ATP | 1.00 |
1.01 |
1.11 |
1.15 |
1.05 |
1.04 |
1.06 |
| KLA/ATP | .99 |
.96 |
.83 |
1.10 |
1.15 |
1.26 |
1.21 |
|
Fgf8 | |
BC048734 |
fibroblast growth factor 8, mRNA (cDNA clone MGC:59627 IMAGE:6513131), complete cds [BC048734] |
KLA | .96 |
.95 |
1.03 |
.96 |
1.06 |
.97 |
.96 |
| ATP | 1.08 |
.94 |
1.07 |
1.10 |
1.00 |
.93 |
1.06 |
| KLA/ATP | 1.03 |
1.02 |
1.04 |
.96 |
1.04 |
.94 |
.94 |
|
Fgf8 | |
NM_010205 |
fibroblast growth factor 8 (Fgf8), mRNA [NM_010205] |
KLA | 1.00 |
1.00 |
1.03 |
1.04 |
1.04 |
1.07 |
1.09 |
| ATP | 1.01 |
1.01 |
1.11 |
1.14 |
1.11 |
1.09 |
1.05 |
| KLA/ATP | 1.00 |
1.04 |
1.14 |
1.18 |
1.15 |
1.09 |
1.04 |
|
Fgf9 | |
NM_013518 |
fibroblast growth factor 9 (Fgf9), mRNA [NM_013518] |
KLA | 1.04 |
1.07 |
1.07 |
1.12 |
.97 |
.96 |
.91 |
| ATP | 1.02 |
1.08 |
.98 |
1.00 |
.94 |
.99 |
.92 |
| KLA/ATP | 1.04 |
1.03 |
1.03 |
1.00 |
.93 |
.93 |
.89 |
|
Fgfr1 | |
M28998 |
gb|Mouse basic fibroblast growth factor receptor (bFGF-R) mRNA, complete cds. [M28998] |
KLA | .82 |
.79 |
.73 |
.66 |
.50 |
.55 |
.65 |
| ATP | 1.01 |
1.08 |
.86 |
.90 |
1.29 |
1.24 |
1.52 |
| KLA/ATP | .85 |
.82 |
.71 |
.71 |
.63 |
.80 |
.85 |
|
Fgfr1 | |
NM_010206 |
fibroblast growth factor receptor 1 (Fgfr1), transcript variant 1, mRNA [NM_010206] |
KLA | .92 |
.86 |
.73 |
.82 |
.79 |
.85 |
.84 |
| ATP | 1.01 |
1.06 |
.92 |
.92 |
1.18 |
1.02 |
1.22 |
| KLA/ATP | .83 |
.83 |
.79 |
.76 |
.83 |
.83 |
.92 |
|
Fgfr2 | |
NM_010207 |
fibroblast growth factor receptor 2 (Fgfr2), transcript variant 1, mRNA [NM_010207] |
KLA | 1.01 |
.98 |
1.00 |
1.01 |
.98 |
1.00 |
.99 |
| ATP | 1.00 |
1.03 |
1.05 |
1.03 |
1.01 |
1.01 |
1.00 |
| KLA/ATP | 1.00 |
1.01 |
1.04 |
1.01 |
.99 |
1.02 |
1.03 |
|
Fgfr3 | |
NM_008010 |
fibroblast growth factor receptor 3 (Fgfr3), mRNA [NM_008010] |
KLA | 1.09 |
1.15 |
1.05 |
1.10 |
1.02 |
1.05 |
1.12 |
| ATP | 1.05 |
.94 |
.98 |
.87 |
.91 |
.95 |
.92 |
| KLA/ATP | 1.13 |
1.11 |
1.10 |
.91 |
.92 |
.93 |
.92 |
|
Fgfr4 | |
AF127140 |
fibroblast growth factor receptor 4 splice variant 17b (Fgfr4) mRNA, partial cds. [AF127140] |
KLA | .96 |
.97 |
1.06 |
.97 |
1.05 |
1.05 |
1.08 |
| ATP | 1.02 |
.98 |
1.07 |
1.23 |
1.15 |
1.18 |
1.31 |
| KLA/ATP | .91 |
1.02 |
1.08 |
1.16 |
1.07 |
1.05 |
1.23 |
|
Fgfr4 | |
NM_008011 |
fibroblast growth factor receptor 4 (Fgfr4), mRNA [NM_008011] |
KLA | 1.08 |
1.11 |
1.09 |
1.06 |
.99 |
1.06 |
1.03 |
| ATP | 1.05 |
.96 |
1.17 |
1.06 |
1.10 |
1.04 |
1.01 |
| KLA/ATP | 1.03 |
.98 |
1.10 |
1.06 |
1.05 |
1.06 |
1.04 |
|
Flna | |
AK044856 |
9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130008E07 product:hypothetical Calponin homology (CH) domain containing protein, full insert sequence. [AK044856] |
KLA | .95 |
.95 |
1.00 |
.99 |
1.02 |
1.10 |
1.00 |
| ATP | .93 |
.94 |
1.02 |
1.08 |
1.04 |
1.01 |
.99 |
| KLA/ATP | 1.02 |
.98 |
.99 |
.98 |
1.02 |
1.08 |
1.02 |
|
Flna | |
NM_010227 |
filamin, alpha (Flna), mRNA [NM_010227] |
KLA | .90 |
.91 |
.92 |
.83 |
1.03 |
1.12 |
.82 |
| ATP | 1.02 |
1.06 |
.77 |
.69 |
.58 |
.69 |
.72 |
| KLA/ATP | .97 |
.90 |
.69 |
.66 |
.49 |
.59 |
.83 |
|
Flnb | |
AK050046 |
adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730006K15 product:filamin, beta, full insert sequence. [AK050046] |
KLA | 5.58 |
4.67 |
5.09 |
3.71 |
3.12 |
1.55 |
1.22 |
| ATP | .97 |
1.04 |
1.40 |
1.56 |
2.09 |
1.87 |
1.06 |
| KLA/ATP | 6.20 |
5.77 |
5.48 |
4.31 |
2.53 |
2.35 |
1.37 |
|
Flnb | |
NM_134080 |
filamin, beta (Flnb), mRNA [NM_134080] |
KLA | 8.86 |
8.95 |
10.89 |
9.75 |
10.94 |
7.28 |
1.54 |
| ATP | 1.03 |
1.08 |
1.17 |
1.39 |
1.82 |
2.72 |
1.01 |
| KLA/ATP | 8.89 |
10.37 |
11.36 |
10.83 |
7.90 |
5.59 |
3.36 |
|
Flnc | |
AK051985 |
12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230030L22 product:weakly similar to CGABP260 ACTIN-BINDING DOMAIN (FRAGMENT) [Gallus gallus], full insert sequence. [AK051985] |
KLA | .97 |
1.04 |
1.01 |
1.03 |
1.01 |
1.05 |
1.06 |
| ATP | 1.02 |
1.04 |
1.00 |
1.02 |
1.02 |
1.10 |
1.06 |
| KLA/ATP | 1.00 |
1.00 |
.98 |
1.07 |
1.03 |
1.07 |
1.04 |
|
Flnc | |
NM_001081185 |
filamin C, gamma (actin binding protein 280) (Flnc), mRNA [NM_001081185] |
KLA | .95 |
1.00 |
1.02 |
1.00 |
.95 |
.98 |
1.05 |
| ATP | 1.02 |
1.01 |
1.11 |
1.37 |
1.04 |
1.04 |
1.13 |
| KLA/ATP | .99 |
1.02 |
.93 |
1.00 |
.90 |
.99 |
1.03 |
|
Fos | |
NM_010234 |
FBJ osteosarcoma oncogene (Fos), mRNA [NM_010234] |
KLA | .42 |
.33 |
.64 |
.61 |
.71 |
.85 |
.71 |
| ATP | 3.48 |
5.46 |
23.78 |
25.22 |
1.71 |
2.36 |
1.50 |
| KLA/ATP | .90 |
1.74 |
5.97 |
8.62 |
1.28 |
2.42 |
4.52 |
|
Gadd45a | |
NM_007836 |
growth arrest and DNA-damage-inducible 45 alpha (Gadd45a), mRNA [NM_007836] |
KLA | .52 |
.72 |
.68 |
.82 |
1.11 |
.73 |
1.91 |
| ATP | .92 |
.85 |
1.20 |
3.38 |
7.86 |
3.35 |
3.64 |
| KLA/ATP | .54 |
.95 |
1.60 |
3.49 |
5.04 |
3.79 |
2.80 |
|
Gadd45b | |
NM_008655 |
growth arrest and DNA-damage-inducible 45 beta (Gadd45b), mRNA [NM_008655] |
KLA | 10.08 |
11.65 |
8.40 |
11.27 |
8.24 |
7.30 |
5.74 |
| ATP | 1.83 |
3.28 |
10.08 |
27.60 |
15.97 |
8.84 |
4.61 |
| KLA/ATP | 9.36 |
14.99 |
21.30 |
45.24 |
49.27 |
21.63 |
22.73 |
|
Gadd45g | |
NM_011817 |
growth arrest and DNA-damage-inducible 45 gamma (Gadd45g), mRNA [NM_011817] |
KLA | 2.18 |
2.14 |
2.95 |
3.62 |
3.22 |
4.69 |
1.21 |
| ATP | 1.01 |
1.74 |
8.49 |
11.83 |
4.60 |
5.94 |
5.94 |
| KLA/ATP | 2.58 |
3.99 |
12.54 |
13.16 |
12.25 |
12.41 |
12.33 |
|
Gna12 | |
M63659 |
gb|Mouse G-alpha-12 protein mRNA, complete cds [M63659] |
KLA | .48 |
.48 |
.49 |
.40 |
.44 |
.59 |
.60 |
| ATP | 1.08 |
1.15 |
1.00 |
1.39 |
1.02 |
.65 |
.73 |
| KLA/ATP | .52 |
.50 |
.51 |
.52 |
.56 |
.66 |
.52 |
|
Gng12 | |
NM_025278 |
guanine nucleotide binding protein (G protein), gamma 12 (Gng12), mRNA [NM_025278] |
KLA | 2.21 |
2.23 |
2.48 |
2.62 |
2.47 |
2.28 |
1.68 |
| ATP | 1.02 |
1.02 |
1.09 |
1.10 |
1.20 |
1.32 |
1.01 |
| KLA/ATP | 2.10 |
2.17 |
2.38 |
2.40 |
1.91 |
1.60 |
1.77 |
|
Grb2 | |
NM_008163 |
growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] |
KLA | .92 |
.88 |
.90 |
1.27 |
1.43 |
1.22 |
1.00 |
| ATP | 1.02 |
.83 |
.51 |
.42 |
.92 |
.70 |
.57 |
| KLA/ATP | .84 |
.77 |
.61 |
.56 |
1.56 |
1.49 |
.52 |
|
Grb2 | |
U07617 |
Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] |
KLA | .83 |
.80 |
.95 |
1.13 |
1.38 |
1.36 |
1.06 |
| ATP | .84 |
.74 |
.51 |
.41 |
.82 |
.74 |
.59 |
| KLA/ATP | .77 |
.70 |
.57 |
.54 |
1.49 |
1.39 |
.53 |
|
Hras1 | |
NM_008284 |
Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] |
KLA | .79 |
.82 |
.77 |
.82 |
.94 |
1.03 |
1.07 |
| ATP | 1.01 |
.95 |
.69 |
.83 |
.79 |
1.12 |
1.15 |
| KLA/ATP | .84 |
.77 |
.61 |
.65 |
.82 |
1.00 |
1.05 |
|
Hspa1a | |
NM_010479 |
heat shock protein 1A (Hspa1a), mRNA [NM_010479] |
KLA | 7.88 |
6.99 |
4.47 |
5.18 |
7.81 |
11.47 |
4.14 |
| ATP | 1.88 |
5.62 |
43.42 |
58.76 |
55.53 |
28.89 |
9.13 |
| KLA/ATP | 7.40 |
7.62 |
28.23 |
54.12 |
70.14 |
43.09 |
22.49 |
|
Hspa1b | |
NM_010478 |
heat shock protein 1B (Hspa1b), mRNA [NM_010478] |
KLA | 5.01 |
4.73 |
3.77 |
3.62 |
4.81 |
6.53 |
3.12 |
| ATP | 1.34 |
3.07 |
14.11 |
17.14 |
17.51 |
11.21 |
4.82 |
| KLA/ATP | 5.04 |
5.15 |
11.63 |
19.94 |
20.84 |
15.79 |
9.30 |
|
Hspa1l | |
NM_013558 |
heat shock protein 1-like (Hspa1l), mRNA [NM_013558] |
KLA | .98 |
1.04 |
1.10 |
1.21 |
1.51 |
1.97 |
1.86 |
| ATP | 1.03 |
1.08 |
1.07 |
1.14 |
.93 |
1.21 |
1.89 |
| KLA/ATP | 1.06 |
1.01 |
.99 |
1.09 |
.97 |
1.39 |
2.87 |
|
Hspa2 | |
NM_008301 |
heat shock protein 2 (Hspa2), transcript variant 1, mRNA [NM_008301] |
KLA | .98 |
.97 |
1.12 |
1.23 |
1.20 |
1.72 |
1.38 |
| ATP | 1.01 |
1.10 |
1.45 |
3.12 |
2.45 |
1.98 |
.98 |
| KLA/ATP | .99 |
1.12 |
1.52 |
2.60 |
2.89 |
2.62 |
1.18 |
|
Hspa8 | |
NM_031165 |
heat shock protein 8 (Hspa8), mRNA [NM_031165] |
KLA | 1.00 |
.98 |
1.27 |
1.18 |
1.45 |
1.60 |
1.31 |
| ATP | 1.22 |
1.18 |
1.07 |
1.44 |
1.07 |
.53 |
.57 |
| KLA/ATP | 1.18 |
1.22 |
1.14 |
1.08 |
.93 |
.82 |
.77 |
|
Hspb1 | |
NM_013560 |
heat shock protein 1 (Hspb1), mRNA [NM_013560] |
KLA | 1.63 |
1.62 |
1.69 |
1.84 |
1.65 |
1.81 |
1.21 |
| ATP | 1.03 |
1.21 |
6.84 |
15.12 |
14.19 |
14.09 |
5.57 |
| KLA/ATP | 1.71 |
1.77 |
3.66 |
12.62 |
12.11 |
12.52 |
7.66 |
|
Ikbkb | |
NM_010546 |
inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] |
KLA | 1.88 |
2.10 |
2.14 |
1.83 |
1.73 |
1.31 |
1.19 |
| ATP | .81 |
.74 |
.55 |
.49 |
.59 |
1.05 |
.96 |
| KLA/ATP | 1.86 |
1.73 |
1.39 |
1.12 |
.89 |
1.17 |
1.24 |
|
Ikbkg | |
AK042138 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] |
KLA | .92 |
.87 |
.78 |
.78 |
.87 |
.88 |
.62 |
| ATP | .84 |
.71 |
.80 |
.50 |
1.15 |
2.33 |
.61 |
| KLA/ATP | .72 |
.69 |
.74 |
.48 |
1.06 |
1.97 |
.68 |
|
Ikbkg | |
NM_010547 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] |
KLA | 1.51 |
1.63 |
1.74 |
1.83 |
1.83 |
1.73 |
1.72 |
| ATP | .80 |
.79 |
.82 |
.75 |
.66 |
2.58 |
2.37 |
| KLA/ATP | 1.43 |
1.42 |
1.17 |
1.04 |
.71 |
1.54 |
3.17 |
|
Ikbkg | |
NM_178590 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] |
KLA | .84 |
.93 |
.86 |
.91 |
1.03 |
.89 |
.88 |
| ATP | 1.03 |
.98 |
.68 |
.56 |
.51 |
.93 |
.68 |
| KLA/ATP | .89 |
.81 |
.55 |
.52 |
.41 |
.67 |
.65 |
|
Il1a | |
NM_010554 |
interleukin 1 alpha (Il1a), mRNA [NM_010554] |
KLA | 32.45 |
35.22 |
31.30 |
20.95 |
28.57 |
18.36 |
19.02 |
| ATP | 1.04 |
1.02 |
2.21 |
5.46 |
11.06 |
32.07 |
3.40 |
| KLA/ATP | 32.02 |
41.20 |
35.12 |
46.91 |
28.76 |
42.72 |
57.80 |
|
Il1b | |
NM_008361 |
interleukin 1 beta (Il1b), mRNA [NM_008361] |
KLA | 149.78 |
133.59 |
100.91 |
116.58 |
86.48 |
89.37 |
64.72 |
| ATP | 3.49 |
13.96 |
61.44 |
70.91 |
82.12 |
162.79 |
28.18 |
| KLA/ATP | 130.32 |
139.00 |
219.12 |
148.17 |
165.44 |
172.57 |
146.98 |
|
Il1r1 | |
NM_008362 |
interleukin 1 receptor, type I (Il1r1), transcript variant 1, mRNA [NM_008362] |
KLA | 1.20 |
1.08 |
1.22 |
1.52 |
2.19 |
2.32 |
1.61 |
| ATP | 1.10 |
.96 |
1.18 |
1.56 |
8.14 |
9.56 |
7.54 |
| KLA/ATP | 1.22 |
1.13 |
1.37 |
1.85 |
4.54 |
6.85 |
8.96 |
|
Il1r2 | |
NM_010555 |
interleukin 1 receptor, type II (Il1r2), mRNA [NM_010555] |
KLA | 1.05 |
1.03 |
1.08 |
1.13 |
1.09 |
1.08 |
1.14 |
| ATP | 1.03 |
1.08 |
1.30 |
1.68 |
1.38 |
1.10 |
1.19 |
| KLA/ATP | 1.08 |
1.14 |
1.17 |
1.27 |
1.10 |
1.11 |
2.03 |
|
Jun | |
NM_010591 |
Jun oncogene (Jun), mRNA [NM_010591] |
KLA | 1.08 |
.96 |
1.09 |
1.09 |
.75 |
.88 |
.81 |
| ATP | 1.26 |
1.48 |
4.45 |
8.73 |
4.02 |
1.16 |
1.99 |
| KLA/ATP | 1.12 |
1.38 |
3.52 |
5.17 |
3.32 |
.49 |
1.42 |
|
Jund | |
NM_010592 |
Jun proto-oncogene related gene d (Jund), mRNA [NM_010592] |
KLA | 1.56 |
1.42 |
1.33 |
1.15 |
1.00 |
.95 |
1.36 |
| ATP | 1.21 |
1.51 |
3.47 |
5.90 |
5.16 |
1.99 |
1.13 |
| KLA/ATP | 1.58 |
1.80 |
2.28 |
4.01 |
4.07 |
2.47 |
1.35 |
|
Kras | |
NM_021284 |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] |
KLA | .53 |
.49 |
.40 |
.42 |
.49 |
.95 |
1.05 |
| ATP | .98 |
1.01 |
1.16 |
1.17 |
1.39 |
1.29 |
1.74 |
| KLA/ATP | .50 |
.47 |
.50 |
.56 |
1.00 |
1.24 |
1.58 |
|
LOC10004 8021 | |
XM_001479354 |
ref|PREDICTED: Mus musculus similar to Guanine nucleotide-binding protein alpha-12 subunit (G alpha-12) (LOC100048021), mRNA [XM_001479354] |
KLA | .29 |
.29 |
.23 |
.19 |
.25 |
.43 |
.47 |
| ATP | 1.03 |
1.08 |
.94 |
.88 |
.78 |
.52 |
.59 |
| KLA/ATP | .32 |
.29 |
.20 |
.22 |
.31 |
.47 |
.36 |
|
Map2k1 | |
NM_008927 |
mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] |
KLA | 1.82 |
2.00 |
2.31 |
2.03 |
2.51 |
2.20 |
1.51 |
| ATP | .99 |
1.14 |
.81 |
.87 |
.90 |
1.57 |
1.11 |
| KLA/ATP | 1.90 |
2.03 |
1.50 |
1.93 |
1.63 |
2.03 |
2.06 |
|
Map2k1ip 1 | |
NM_019920 |
mitogen-activated protein kinase kinase 1 interacting protein 1 (Map2k1ip1), mRNA [NM_019920] |
KLA | .75 |
.74 |
.83 |
.96 |
.88 |
.95 |
.85 |
| ATP | 1.00 |
.82 |
1.17 |
1.01 |
1.84 |
1.42 |
1.37 |
| KLA/ATP | .69 |
.70 |
1.03 |
.79 |
1.54 |
1.34 |
1.05 |
|
Map2k2 | |
NM_023138 |
mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] |
KLA | .96 |
1.01 |
1.09 |
.99 |
1.11 |
1.15 |
1.42 |
| ATP | 1.07 |
1.05 |
.74 |
.86 |
1.04 |
1.16 |
1.21 |
| KLA/ATP | 1.14 |
1.03 |
.68 |
.78 |
.85 |
1.01 |
1.20 |
|
Map2k3 | |
NM_008928 |
mitogen-activated protein kinase kinase 3 (Map2k3), mRNA [NM_008928] |
KLA | .88 |
.88 |
.73 |
.65 |
.99 |
1.34 |
.92 |
| ATP | 1.04 |
1.09 |
.89 |
1.62 |
1.93 |
1.75 |
1.17 |
| KLA/ATP | 1.00 |
.92 |
.66 |
1.21 |
1.80 |
2.24 |
2.10 |
|
Map2k4 | |
NM_009157 |
mitogen-activated protein kinase kinase 4 (Map2k4), mRNA [NM_009157] |
KLA | 3.67 |
3.75 |
4.23 |
3.90 |
3.30 |
1.87 |
1.12 |
| ATP | 1.05 |
1.11 |
1.04 |
.93 |
1.16 |
2.62 |
1.02 |
| KLA/ATP | 3.70 |
4.13 |
3.27 |
4.13 |
2.98 |
3.03 |
1.82 |
|
Map2k5 | |
NM_011840 |
mitogen-activated protein kinase kinase 5 (Map2k5), mRNA [NM_011840] |
KLA | .80 |
.86 |
.78 |
.68 |
.75 |
.86 |
1.09 |
| ATP | .97 |
.90 |
.71 |
.85 |
.81 |
.98 |
.80 |
| KLA/ATP | .83 |
.73 |
.50 |
.56 |
.63 |
.98 |
.79 |
|
Map2k6 | |
NM_011943 |
mitogen-activated protein kinase kinase 6 (Map2k6), mRNA [NM_011943] |
KLA | .68 |
.67 |
.64 |
.67 |
.62 |
.59 |
.61 |
| ATP | 1.02 |
1.12 |
1.04 |
1.10 |
.79 |
.61 |
.61 |
| KLA/ATP | .73 |
.69 |
.71 |
.74 |
.66 |
.62 |
.98 |
|
Map2k7 | |
BC070467 |
mitogen activated protein kinase kinase 7, mRNA (cDNA clone MGC:96654 IMAGE:30615302), complete cds [BC070467] |
KLA | .77 |
.79 |
.88 |
.77 |
.97 |
.96 |
1.27 |
| ATP | 1.11 |
1.26 |
.93 |
1.19 |
1.13 |
1.45 |
1.16 |
| KLA/ATP | .89 |
.88 |
.59 |
.89 |
.86 |
1.32 |
1.28 |
|
Map2k7 | |
NM_001042557 |
mitogen-activated protein kinase kinase 7 (Map2k7), transcript variant 1, mRNA [NM_001042557] |
KLA | .96 |
.95 |
1.02 |
.96 |
.95 |
1.09 |
1.19 |
| ATP | 1.02 |
1.07 |
.88 |
.97 |
.93 |
1.10 |
1.17 |
| KLA/ATP | 1.01 |
.99 |
.80 |
.87 |
.76 |
1.21 |
1.16 |
|
Map3k1 | |
NM_011945 |
mitogen-activated protein kinase kinase kinase 1 (Map3k1), mRNA [NM_011945] |
KLA | .30 |
.25 |
.37 |
.56 |
.68 |
1.07 |
.85 |
| ATP | .88 |
.86 |
1.26 |
1.04 |
1.07 |
.77 |
.78 |
| KLA/ATP | .28 |
.24 |
.59 |
.99 |
1.49 |
.97 |
1.24 |
|
Map3k11 | |
NM_022012 |
mitogen-activated protein kinase kinase kinase 11 (Map3k11), mRNA [NM_022012] |
KLA | .85 |
.93 |
.96 |
1.04 |
1.39 |
1.23 |
1.05 |
| ATP | 1.06 |
1.10 |
.62 |
.85 |
.81 |
1.21 |
1.03 |
| KLA/ATP | 1.05 |
.90 |
.51 |
.86 |
.93 |
1.31 |
1.80 |
|
Map3k12 | |
NM_009582 |
mitogen-activated protein kinase kinase kinase 12 (Map3k12), mRNA [NM_009582] |
KLA | .46 |
.44 |
.49 |
.55 |
.61 |
.70 |
.66 |
| ATP | .93 |
.90 |
.93 |
.81 |
.54 |
.60 |
1.29 |
| KLA/ATP | .45 |
.44 |
.50 |
.56 |
.61 |
.62 |
.85 |
|
Map3k12 | |
U09541 |
CD1 protein kinase mRNA, partial cds. [U09541] |
KLA | .73 |
.66 |
.64 |
.72 |
.68 |
.73 |
.82 |
| ATP | .97 |
.98 |
.83 |
.86 |
.62 |
.68 |
1.32 |
| KLA/ATP | .70 |
.64 |
.67 |
.69 |
.63 |
.69 |
.94 |
|
Map3k13 | |
NM_172821 |
mitogen-activated protein kinase kinase kinase 13 (Map3k13), mRNA [NM_172821] |
KLA | .96 |
.97 |
.98 |
1.02 |
1.02 |
1.05 |
1.02 |
| ATP | 1.03 |
1.02 |
.89 |
.93 |
1.00 |
1.05 |
.92 |
| KLA/ATP | 1.02 |
.97 |
.99 |
.91 |
.95 |
.98 |
1.08 |
|
Map3k14 | |
NM_016896 |
mitogen-activated protein kinase kinase kinase 14 (Map3k14), mRNA [NM_016896] |
KLA | .32 |
.30 |
.40 |
.52 |
1.08 |
1.14 |
.94 |
| ATP | 1.18 |
1.24 |
1.13 |
.85 |
.82 |
.84 |
.99 |
| KLA/ATP | .33 |
.30 |
.34 |
.50 |
1.02 |
.84 |
1.43 |
|
Map3k2 | |
NM_011946 |
mitogen-activated protein kinase kinase kinase 2 (Map3k2), mRNA [NM_011946] |
KLA | .80 |
.79 |
.74 |
.79 |
.93 |
1.00 |
1.09 |
| ATP | .99 |
.97 |
1.05 |
1.13 |
1.79 |
1.27 |
1.14 |
| KLA/ATP | .81 |
.76 |
.77 |
.84 |
1.39 |
1.29 |
1.26 |
|
Map3k3 | |
NM_011947 |
mitogen-activated protein kinase kinase kinase 3 (Map3k3), mRNA [NM_011947] |
KLA | .60 |
.63 |
.60 |
.58 |
.81 |
1.03 |
1.26 |
| ATP | .97 |
.91 |
.55 |
.58 |
.71 |
.81 |
.99 |
| KLA/ATP | .68 |
.57 |
.42 |
.53 |
.61 |
.85 |
1.23 |
|
Map3k4 | |
AK035823 |
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630008E23 product:mitogen activated protein kinase kinase kinase 4, full insert sequence. [AK035823] |
KLA | 1.04 |
.92 |
1.04 |
.92 |
.96 |
.98 |
1.01 |
| ATP | 1.00 |
.95 |
.99 |
.99 |
1.01 |
.95 |
1.01 |
| KLA/ATP | .99 |
1.06 |
.94 |
1.02 |
1.03 |
1.00 |
.97 |
|
Map3k4 | |
NM_011948 |
mitogen-activated protein kinase kinase kinase 4 (Map3k4), mRNA [NM_011948] |
KLA | .56 |
.57 |
.58 |
.66 |
.81 |
.94 |
.99 |
| ATP | .97 |
.93 |
1.13 |
.98 |
.65 |
.60 |
.95 |
| KLA/ATP | .54 |
.54 |
.64 |
.61 |
.69 |
.70 |
.91 |
|
Map3k5 | |
NM_008580 |
mitogen-activated protein kinase kinase kinase 5 (Map3k5), mRNA [NM_008580] |
KLA | 1.85 |
1.97 |
1.17 |
.82 |
.57 |
.47 |
.49 |
| ATP | 1.06 |
1.05 |
.94 |
1.22 |
1.55 |
.91 |
.32 |
| KLA/ATP | 2.00 |
1.82 |
.95 |
.91 |
.60 |
.34 |
.28 |
|
Map3k6 | |
NM_016693 |
mitogen-activated protein kinase kinase kinase 6 (Map3k6), mRNA [NM_016693] |
KLA | 1.43 |
1.27 |
.88 |
.74 |
.97 |
1.03 |
1.16 |
| ATP | .99 |
.95 |
1.11 |
1.07 |
1.52 |
1.92 |
.71 |
| KLA/ATP | 1.44 |
1.28 |
1.17 |
.98 |
1.00 |
.74 |
.51 |
|
Map3k7 | |
NM_172688 |
mitogen-activated protein kinase kinase kinase 7 (Map3k7), mRNA [NM_172688] |
KLA | 1.48 |
1.49 |
1.51 |
1.24 |
1.21 |
1.19 |
1.61 |
| ATP | 1.10 |
1.16 |
1.03 |
1.03 |
1.12 |
1.61 |
1.61 |
| KLA/ATP | 1.43 |
1.56 |
1.05 |
1.15 |
.85 |
1.48 |
1.76 |
|
Map3k7ip 1 | |
NM_025609 |
mitogen-activated protein kinase kinase kinase 7 interacting protein 1 (Map3k7ip1), mRNA [NM_025609] |
KLA | .32 |
.30 |
.35 |
.56 |
.67 |
.82 |
.76 |
| ATP | .95 |
.81 |
.80 |
.42 |
.35 |
.40 |
.80 |
| KLA/ATP | .33 |
.30 |
.37 |
.20 |
.45 |
.62 |
.65 |
|
Map3k7ip 2 | |
AK086230 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930015C19 product:inferred: Mus musculus, Similar to TAK1-binding protein 2; KIAA0733 protein, clone MGC:8010 IMAGE:3586132, mRNA, complete cds, full insert sequence. [A |
KLA | 1.14 |
1.02 |
1.07 |
1.03 |
1.13 |
1.02 |
.96 |
| ATP | 1.00 |
.88 |
.92 |
.90 |
1.06 |
.96 |
.94 |
| KLA/ATP | 1.05 |
1.00 |
.90 |
.98 |
1.02 |
.97 |
.97 |
|
Map3k7ip 2 | |
NM_138667 |
mitogen-activated protein kinase kinase kinase 7 interacting protein 2 (Map3k7ip2), mRNA [NM_138667] |
KLA | 3.43 |
3.22 |
3.19 |
2.41 |
2.13 |
1.51 |
1.10 |
| ATP | 1.08 |
1.08 |
.86 |
.81 |
1.30 |
1.32 |
1.02 |
| KLA/ATP | 3.34 |
3.66 |
3.00 |
2.58 |
1.80 |
1.52 |
1.61 |
|
Map3k8 | |
D13759 |
cot mRNA for proto-oncogene protein, complete cds. [D13759] |
KLA | 11.38 |
11.64 |
13.24 |
13.31 |
10.92 |
5.26 |
3.31 |
| ATP | 1.36 |
1.09 |
1.75 |
6.27 |
10.51 |
3.58 |
1.60 |
| KLA/ATP | 12.58 |
11.57 |
8.93 |
14.10 |
13.92 |
4.98 |
4.09 |
|
Map4k1 | |
NM_008279 |
mitogen-activated protein kinase kinase kinase kinase 1 (Map4k1), mRNA [NM_008279] |
KLA | .55 |
.56 |
.51 |
.47 |
.41 |
.37 |
.40 |
| ATP | .92 |
.84 |
1.18 |
1.05 |
.74 |
.36 |
.54 |
| KLA/ATP | .55 |
.54 |
.63 |
.57 |
.54 |
.34 |
.30 |
|
Map4k2 | |
AK154164 |
NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F630005M21 product:mitogen activated protein kinase kinase kinase kinase 2, full insert sequence [AK154164] |
KLA | .82 |
.77 |
.80 |
.78 |
.78 |
.75 |
.72 |
| ATP | 1.05 |
1.14 |
.99 |
.93 |
.68 |
.67 |
.55 |
| KLA/ATP | .76 |
.81 |
.74 |
.74 |
.72 |
.69 |
.53 |
|
Map4k2 | |
NM_009006 |
mitogen-activated protein kinase kinase kinase kinase 2 (Map4k2), mRNA [NM_009006] |
KLA | .83 |
.84 |
.93 |
.88 |
.89 |
.88 |
.96 |
| ATP | 1.18 |
1.23 |
1.06 |
1.34 |
.87 |
.92 |
1.01 |
| KLA/ATP | 1.00 |
.90 |
.79 |
1.09 |
.84 |
.78 |
1.04 |
|
Map4k3 | |
NM_001081357 |
mitogen-activated protein kinase kinase kinase kinase 3 (Map4k3), mRNA [NM_001081357] |
KLA | .45 |
.46 |
.67 |
1.09 |
1.60 |
2.12 |
1.48 |
| ATP | 1.02 |
1.13 |
1.00 |
1.05 |
.64 |
.52 |
1.88 |
| KLA/ATP | .48 |
.43 |
.53 |
.79 |
.61 |
.58 |
2.44 |
|
Map4k4 | |
NM_008696 |
mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4), mRNA [NM_008696] |
KLA | 1.03 |
.91 |
.82 |
.89 |
.90 |
1.09 |
.91 |
| ATP | 1.01 |
.90 |
1.01 |
1.11 |
1.53 |
1.84 |
1.11 |
| KLA/ATP | .97 |
.85 |
.84 |
.83 |
1.16 |
1.34 |
1.41 |
|
Mapk1 | |
NM_001038663 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] |
KLA | .97 |
1.03 |
.93 |
.86 |
.79 |
1.01 |
1.04 |
| ATP | .96 |
1.18 |
1.01 |
1.13 |
.84 |
1.04 |
1.16 |
| KLA/ATP | .99 |
.99 |
.84 |
.87 |
.63 |
.96 |
1.26 |
|
Mapk1 | |
NM_011949 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] |
KLA | .88 |
.80 |
.80 |
.73 |
.75 |
.76 |
.65 |
| ATP | .97 |
.96 |
1.06 |
.88 |
.90 |
.68 |
.48 |
| KLA/ATP | .82 |
.81 |
.78 |
.65 |
.64 |
.64 |
.45 |
|
Mapk10 | |
AK076990 |
adult male testis cDNA, RIKEN full-length enriched library, clone:4930597C01 product:mitogen activated protein kinase 10, full insert sequence. [AK076990] |
KLA | 1.03 |
1.05 |
.98 |
1.04 |
.94 |
.95 |
1.02 |
| ATP | 1.00 |
.99 |
1.06 |
.97 |
1.01 |
.96 |
.99 |
| KLA/ATP | 1.07 |
1.01 |
.95 |
1.05 |
.82 |
.95 |
.87 |
|
Mapk10 | |
NM_009158 |
mitogen-activated protein kinase 10 (Mapk10), transcript variant 1, mRNA [NM_009158] |
KLA | .95 |
1.00 |
.97 |
1.01 |
.99 |
1.01 |
.95 |
| ATP | 1.01 |
1.02 |
.98 |
1.01 |
1.04 |
1.01 |
.99 |
| KLA/ATP | 1.05 |
.99 |
1.01 |
.98 |
.92 |
.97 |
.98 |
|
Mapk11 | |
NM_011161 |
mitogen-activated protein kinase 11 (Mapk11), mRNA [NM_011161] |
KLA | 1.28 |
1.30 |
1.41 |
1.46 |
1.58 |
1.29 |
.98 |
| ATP | .96 |
.95 |
.89 |
.82 |
.79 |
1.09 |
.85 |
| KLA/ATP | 1.44 |
1.42 |
1.32 |
1.23 |
1.23 |
.74 |
.66 |
|
Mapk12 | |
NM_013871 |
mitogen-activated protein kinase 12 (Mapk12), mRNA [NM_013871] |
KLA | .94 |
.86 |
.87 |
.81 |
.77 |
.68 |
.49 |
| ATP | .97 |
.83 |
.92 |
.90 |
.86 |
.90 |
.51 |
| KLA/ATP | .91 |
.89 |
.88 |
.85 |
1.12 |
1.14 |
.53 |
|
Mapk13 | |
NM_011950 |
mitogen-activated protein kinase 13 (Mapk13), mRNA [NM_011950] |
KLA | 1.22 |
1.21 |
1.35 |
1.26 |
1.24 |
1.13 |
1.01 |
| ATP | 1.08 |
1.00 |
1.20 |
1.20 |
1.13 |
1.22 |
1.39 |
| KLA/ATP | 1.22 |
1.27 |
1.30 |
1.30 |
1.21 |
1.11 |
1.47 |
|
Mapk14 | |
NM_011951 |
mitogen-activated protein kinase 14 (Mapk14), mRNA [NM_011951] |
KLA | .70 |
.70 |
.62 |
.54 |
.67 |
.88 |
1.11 |
| ATP | 1.03 |
.98 |
.87 |
.69 |
.48 |
.78 |
.66 |
| KLA/ATP | .74 |
.68 |
.52 |
.46 |
.38 |
.45 |
.62 |
|
Mapk3 | |
NM_011952 |
mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] |
KLA | .81 |
.85 |
.88 |
.72 |
.79 |
.73 |
.90 |
| ATP | 1.13 |
1.30 |
.92 |
1.48 |
1.08 |
.68 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
.66 |
1.13 |
.77 |
.77 |
1.16 |
|
Mapk7 | |
NM_011841 |
mitogen-activated protein kinase 7 (Mapk7), mRNA [NM_011841] |
KLA | .46 |
.43 |
.53 |
.80 |
1.03 |
1.38 |
1.55 |
| ATP | .96 |
.80 |
.84 |
.62 |
1.76 |
2.01 |
1.67 |
| KLA/ATP | .39 |
.40 |
.47 |
.50 |
2.55 |
1.93 |
2.48 |
|
Mapk8 | |
AK162915 |
adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330031O19 product:mitogen activated protein kinase 8, full insert sequence [AK162915] |
KLA | .94 |
.86 |
.80 |
.83 |
.77 |
.85 |
.83 |
| ATP | 1.08 |
1.12 |
.94 |
.80 |
.83 |
.71 |
.75 |
| KLA/ATP | .83 |
.81 |
.80 |
.74 |
.74 |
.75 |
.67 |
|
Mapk8 | |
AK163829 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130070A06 product:mitogen activated protein kinase 8, full insert sequence [AK163829] |
KLA | .65 |
.61 |
.66 |
.70 |
.90 |
1.02 |
1.03 |
| ATP | .99 |
.94 |
1.68 |
1.44 |
1.75 |
1.84 |
1.10 |
| KLA/ATP | .63 |
.67 |
1.11 |
1.00 |
2.01 |
1.68 |
1.15 |
|
Mapk8 | |
NM_016700 |
mitogen-activated protein kinase 8 (Mapk8), mRNA [NM_016700] |
KLA | .96 |
1.00 |
.94 |
.96 |
.94 |
.99 |
1.04 |
| ATP | 1.01 |
1.05 |
1.01 |
.99 |
1.03 |
.98 |
1.02 |
| KLA/ATP | .96 |
.97 |
.96 |
.97 |
.93 |
.94 |
.96 |
|
Mapk8ip1
| |
AK053819 |
0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130310D04 product:unclassifiable, full insert sequence. [AK053819] |
KLA | 1.02 |
.96 |
.99 |
1.00 |
1.00 |
.96 |
.96 |
| ATP | 1.00 |
.99 |
1.01 |
.99 |
1.08 |
.99 |
1.00 |
| KLA/ATP | .95 |
1.02 |
.99 |
1.03 |
1.26 |
1.06 |
1.02 |
|
Mapk8ip1
| |
NM_011162 |
mitogen-activated protein kinase 8 interacting protein 1 (Mapk8ip1), mRNA [NM_011162] |
KLA | .95 |
.95 |
.90 |
.81 |
.87 |
.88 |
.93 |
| ATP | 1.05 |
1.11 |
1.06 |
.98 |
.94 |
.98 |
.98 |
| KLA/ATP | .97 |
.84 |
.91 |
.88 |
.94 |
.98 |
.84 |
|
Mapk8ip2
| |
NM_021921 |
mitogen-activated protein kinase 8 interacting protein 2 (Mapk8ip2), mRNA [NM_021921] |
KLA | .94 |
1.03 |
1.00 |
.99 |
1.06 |
1.05 |
.98 |
| ATP | .97 |
1.09 |
1.01 |
1.02 |
.96 |
1.04 |
1.09 |
| KLA/ATP | .98 |
.95 |
1.01 |
1.16 |
1.07 |
1.01 |
1.03 |
|
Mapk8ip3
| |
AK035619 |
adult male urinary bladder cDNA, RIKEN full-length enriched library, clone:9530077J01 product:mitogen-activated protein kinase 8 interacting protein 3, full insert sequence. [AK035619] |
KLA | .81 |
.81 |
.78 |
.77 |
.83 |
.83 |
1.03 |
| ATP | .96 |
.93 |
.86 |
.80 |
.72 |
.73 |
1.36 |
| KLA/ATP | .74 |
.79 |
.81 |
.74 |
.71 |
.76 |
.87 |
|
Mapk8ip3
| |
NM_013931 |
mitogen-activated protein kinase 8 interacting protein 3 (Mapk8ip3), mRNA [NM_013931] |
KLA | .84 |
.81 |
.98 |
1.24 |
1.63 |
1.45 |
1.08 |
| ATP | 1.09 |
.98 |
1.14 |
.69 |
1.46 |
1.58 |
1.32 |
| KLA/ATP | .89 |
.78 |
.99 |
.55 |
1.55 |
1.39 |
1.80 |
|
Mapk9 | |
NM_016961 |
mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] |
KLA | 1.28 |
1.37 |
1.59 |
1.60 |
1.61 |
1.43 |
1.38 |
| ATP | 1.03 |
.99 |
.74 |
.71 |
.79 |
1.20 |
1.01 |
| KLA/ATP | 1.53 |
1.30 |
1.07 |
.99 |
.83 |
1.10 |
1.40 |
|
Mapk9 | |
NM_207692 |
mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] |
KLA | 1.39 |
1.53 |
1.69 |
1.69 |
1.55 |
1.44 |
1.51 |
| ATP | .95 |
.92 |
.75 |
.85 |
.70 |
1.46 |
1.17 |
| KLA/ATP | 1.37 |
1.35 |
.99 |
1.18 |
.91 |
1.22 |
1.62 |
|
Mapkapk2
| |
NM_008551 |
MAP kinase-activated protein kinase 2 (Mapkapk2), mRNA [NM_008551] |
KLA | 5.20 |
5.49 |
5.81 |
5.35 |
5.43 |
2.98 |
2.19 |
| ATP | 1.04 |
1.12 |
1.00 |
1.50 |
1.88 |
2.43 |
1.01 |
| KLA/ATP | 5.63 |
5.95 |
4.08 |
4.71 |
3.33 |
2.24 |
2.50 |
|
Mapkapk3
| |
NM_178907 |
mitogen-activated protein kinase-activated protein kinase 3 (Mapkapk3), mRNA [NM_178907] |
KLA | 1.39 |
1.20 |
.92 |
.63 |
.69 |
.77 |
1.17 |
| ATP | 1.08 |
.93 |
.62 |
.89 |
2.84 |
2.80 |
1.08 |
| KLA/ATP | 1.51 |
1.23 |
.77 |
.81 |
1.96 |
2.29 |
1.74 |
|
Mapkapk5
| |
NM_010765 |
MAP kinase-activated protein kinase 5 (Mapkapk5), mRNA [NM_010765] |
KLA | 1.07 |
1.10 |
1.11 |
1.07 |
1.16 |
1.24 |
1.40 |
| ATP | .97 |
1.00 |
.99 |
.99 |
1.05 |
1.18 |
1.12 |
| KLA/ATP | 1.05 |
1.10 |
1.04 |
.87 |
.92 |
1.06 |
1.20 |
|
Mapt | |
NM_001038609 |
microtubule-associated protein tau (Mapt), transcript variant 1, mRNA [NM_001038609] |
KLA | .96 |
1.10 |
1.00 |
.97 |
.92 |
1.01 |
1.00 |
| ATP | .96 |
1.05 |
1.10 |
.94 |
1.06 |
1.03 |
.93 |
| KLA/ATP | .99 |
1.07 |
1.06 |
.94 |
1.18 |
1.05 |
.98 |
|
Max | |
NM_008558 |
Max protein (Max), mRNA [NM_008558] |
KLA | 3.40 |
3.25 |
4.09 |
4.53 |
3.19 |
2.71 |
1.19 |
| ATP | 1.17 |
1.09 |
1.13 |
.86 |
1.24 |
1.40 |
1.09 |
| KLA/ATP | 3.14 |
3.36 |
5.49 |
3.83 |
4.35 |
2.96 |
1.67 |
|
Mef2c | |
AK044643 |
adult retina cDNA, RIKEN full-length enriched library, clone:A930029G05 product:unclassifiable, full insert sequence. [AK044643] |
KLA | .97 |
.95 |
.99 |
.99 |
.96 |
.92 |
.97 |
| ATP | 1.03 |
1.09 |
1.08 |
.96 |
1.03 |
.85 |
.90 |
| KLA/ATP | .92 |
.99 |
.94 |
.83 |
.90 |
.93 |
.91 |
|
Mef2c | |
NM_025282 |
myocyte enhancer factor 2C (Mef2c), mRNA [NM_025282] |
KLA | .36 |
.35 |
.34 |
.44 |
.25 |
.31 |
.24 |
| ATP | 1.10 |
.84 |
.84 |
.97 |
.39 |
.19 |
.41 |
| KLA/ATP | .35 |
.32 |
.41 |
.44 |
.33 |
.19 |
.18 |
|
Mknk1 | |
NM_021461 |
MAP kinase-interacting serine/threonine kinase 1 (Mknk1), mRNA [NM_021461] |
KLA | .78 |
.81 |
.88 |
.86 |
.98 |
1.12 |
.93 |
| ATP | 1.04 |
1.03 |
1.03 |
1.07 |
.70 |
.67 |
1.09 |
| KLA/ATP | .83 |
.83 |
.81 |
.84 |
.66 |
.88 |
1.12 |
|
Mknk2 | |
NM_021462 |
MAP kinase-interacting serine/threonine kinase 2 (Mknk2), mRNA [NM_021462] |
KLA | .19 |
.18 |
.16 |
.15 |
.20 |
.50 |
.62 |
| ATP | .89 |
.86 |
1.35 |
2.05 |
1.76 |
1.52 |
1.29 |
| KLA/ATP | .19 |
.17 |
.32 |
.99 |
1.61 |
2.33 |
1.97 |
|
Mm.13849
| |
158937311 |
Unknown |
KLA | 1.71 |
1.69 |
1.64 |
1.89 |
1.78 |
1.97 |
1.25 |
| ATP | 1.00 |
1.23 |
5.40 |
7.14 |
6.79 |
7.89 |
4.71 |
| KLA/ATP | 1.73 |
1.75 |
5.04 |
7.35 |
8.18 |
7.92 |
6.07 |
|
Mm.15898 1 | |
142388182 |
Unknown |
KLA | .25 |
.22 |
.31 |
.50 |
.85 |
1.11 |
.83 |
| ATP | 1.02 |
.94 |
1.31 |
.76 |
.73 |
.96 |
.92 |
| KLA/ATP | .24 |
.22 |
.34 |
.38 |
1.16 |
.96 |
1.23 |
|
Mm.1741 | |
31982052 |
Unknown |
KLA | 4.05 |
3.90 |
3.12 |
3.55 |
4.00 |
3.37 |
2.25 |
| ATP | 1.01 |
1.01 |
1.44 |
2.36 |
3.07 |
3.54 |
1.27 |
| KLA/ATP | 4.19 |
3.74 |
4.02 |
4.02 |
3.13 |
2.82 |
3.33 |
|
Mm.20374 7 | |
146149233 |
Unknown |
KLA | .34 |
.30 |
.28 |
.41 |
.80 |
1.31 |
1.29 |
| ATP | .93 |
.83 |
.82 |
.76 |
.43 |
.46 |
.88 |
| KLA/ATP | .30 |
.28 |
.27 |
.27 |
.27 |
.51 |
1.11 |
|
Mm.21499 4 | |
148540002 |
Unknown |
KLA | 1.04 |
1.08 |
1.14 |
1.05 |
1.07 |
1.18 |
1.23 |
| ATP | 1.02 |
.99 |
1.08 |
1.05 |
1.00 |
1.01 |
1.01 |
| KLA/ATP | 1.02 |
1.11 |
1.10 |
.99 |
1.03 |
1.10 |
1.11 |
|
Mm.23904 1 | |
145301574 |
Unknown |
KLA | 4.48 |
4.00 |
7.76 |
10.91 |
8.92 |
5.66 |
4.86 |
| ATP | 4.23 |
6.26 |
25.25 |
43.30 |
8.11 |
8.22 |
2.78 |
| KLA/ATP | 6.59 |
8.15 |
19.54 |
43.73 |
11.92 |
15.37 |
15.81 |
|
Mm.27558 4 | |
142385539 |
Unknown |
KLA | .18 |
.17 |
.27 |
.47 |
.60 |
.43 |
.37 |
| ATP | 1.13 |
1.12 |
1.06 |
1.06 |
1.18 |
.46 |
.89 |
| KLA/ATP | .16 |
.16 |
.24 |
.33 |
.42 |
.35 |
.31 |
|
Mm.27970
| |
13994135 |
Unknown |
KLA | 1.06 |
1.11 |
1.16 |
1.07 |
1.11 |
1.08 |
.95 |
| ATP | 1.02 |
1.09 |
1.05 |
1.05 |
.94 |
1.16 |
1.32 |
| KLA/ATP | 1.10 |
1.19 |
1.11 |
1.04 |
1.08 |
1.02 |
1.33 |
|
Mm.28964 6 | |
146198766 |
Unknown |
KLA | .61 |
.59 |
.55 |
.58 |
.52 |
.72 |
.60 |
| ATP | 1.13 |
1.14 |
.82 |
.79 |
.59 |
.39 |
.61 |
| KLA/ATP | .66 |
.61 |
.58 |
.71 |
.52 |
.38 |
.50 |
|
Mm.29105 8 | |
157057193 |
Unknown |
KLA | 1.02 |
.94 |
.97 |
.97 |
1.03 |
1.00 |
1.00 |
| ATP | 1.03 |
1.01 |
1.10 |
.95 |
.95 |
1.00 |
1.03 |
| KLA/ATP | .97 |
.93 |
1.06 |
1.02 |
1.04 |
.94 |
1.02 |
|
Mm.32574 6 | |
118130017 |
Unknown |
KLA | .71 |
.67 |
.65 |
.62 |
.73 |
.74 |
.83 |
| ATP | 1.03 |
.83 |
.89 |
.79 |
.93 |
1.17 |
.78 |
| KLA/ATP | .77 |
.62 |
.61 |
.55 |
.79 |
1.11 |
.78 |
|
Mm.33050 7 | |
67906182 |
Unknown |
KLA | .94 |
.98 |
.99 |
1.03 |
1.05 |
1.07 |
.98 |
| ATP | .95 |
1.02 |
.97 |
.98 |
.99 |
1.05 |
1.02 |
| KLA/ATP | 1.02 |
1.05 |
1.01 |
1.03 |
.99 |
.98 |
.97 |
|
Mm.33138 9 | |
158508469 |
Unknown |
KLA | .80 |
.79 |
.81 |
.82 |
.72 |
.64 |
.50 |
| ATP | .95 |
.85 |
.56 |
.48 |
.30 |
.33 |
.46 |
| KLA/ATP | .71 |
.64 |
.50 |
.41 |
.33 |
.32 |
.42 |
|
Mm.33981 2 | |
6679780 |
Unknown |
KLA | 1.10 |
1.14 |
1.09 |
1.05 |
1.05 |
1.08 |
1.01 |
| ATP | .95 |
1.06 |
2.35 |
11.15 |
2.46 |
1.50 |
1.03 |
| KLA/ATP | 1.02 |
1.05 |
2.05 |
8.78 |
2.65 |
1.76 |
1.02 |
|
Mm.35799 0 | |
21687185 |
Unknown |
KLA | 1.18 |
1.20 |
1.19 |
1.23 |
1.18 |
1.19 |
1.10 |
| ATP | .97 |
1.07 |
1.11 |
1.19 |
1.01 |
1.15 |
.98 |
| KLA/ATP | 1.06 |
1.29 |
1.19 |
1.29 |
1.19 |
1.10 |
1.10 |
|
Mm.41274 5 | |
110681696 |
Unknown |
KLA | .97 |
1.07 |
1.11 |
1.07 |
1.38 |
1.63 |
1.35 |
| ATP | 1.06 |
1.09 |
1.05 |
1.29 |
1.04 |
.50 |
.56 |
| KLA/ATP | 1.11 |
1.12 |
1.04 |
1.11 |
.92 |
.83 |
.74 |
|
Mm.41292 2 | |
145966829 |
Unknown |
KLA | 3.65 |
3.76 |
3.75 |
3.79 |
3.42 |
1.75 |
1.10 |
| ATP | 1.11 |
1.17 |
1.04 |
.90 |
1.37 |
2.90 |
1.00 |
| KLA/ATP | 3.31 |
3.97 |
3.38 |
3.84 |
3.04 |
3.31 |
2.09 |
|
Mm.43824 7 | |
118130208 |
Unknown |
KLA | 1.43 |
1.43 |
1.34 |
1.56 |
1.23 |
1.37 |
1.20 |
| ATP | .98 |
1.05 |
1.20 |
1.46 |
1.21 |
1.28 |
1.08 |
| KLA/ATP | 1.37 |
1.34 |
1.71 |
1.70 |
1.41 |
1.42 |
1.32 |
|
Mm.44077 3 | |
124517717 |
Unknown |
KLA | .69 |
.69 |
.71 |
.76 |
.71 |
.73 |
.58 |
| ATP | .93 |
.96 |
1.01 |
.85 |
.73 |
.76 |
.57 |
| KLA/ATP | .60 |
.65 |
.75 |
.80 |
.76 |
.66 |
.55 |
|
Mm.4424 | |
110225367 |
Unknown |
KLA | .99 |
.93 |
1.01 |
1.02 |
1.00 |
.92 |
1.00 |
| ATP | .98 |
1.03 |
3.11 |
1.13 |
1.19 |
1.03 |
1.11 |
| KLA/ATP | .95 |
.97 |
.97 |
.96 |
.93 |
1.01 |
.99 |
|
Mm.44591 2 | |
9506452 |
Unknown |
KLA | .98 |
.99 |
1.00 |
1.07 |
.99 |
.98 |
1.07 |
| ATP | 1.02 |
1.05 |
.94 |
.96 |
1.01 |
1.00 |
.94 |
| KLA/ATP | 1.01 |
1.08 |
1.04 |
.92 |
.92 |
1.00 |
1.03 |
|
Mm.44981 2 | |
84370346 |
Unknown |
KLA | 1.01 |
.97 |
.97 |
.96 |
.96 |
1.00 |
.94 |
| ATP | .96 |
.95 |
1.01 |
.93 |
.95 |
1.01 |
1.02 |
| KLA/ATP | .93 |
.92 |
.94 |
.91 |
.97 |
.98 |
.98 |
|
Mm.45044
| |
133892959 |
Unknown |
KLA | .51 |
.47 |
.52 |
.83 |
1.25 |
1.16 |
.60 |
| ATP | 1.09 |
.78 |
.80 |
.63 |
.83 |
.89 |
.41 |
| KLA/ATP | .49 |
.42 |
.44 |
.39 |
.89 |
1.04 |
.41 |
|
Mm.45825 9 | |
116292181 |
Unknown |
KLA | .84 |
.86 |
.91 |
.85 |
.98 |
.98 |
1.00 |
| ATP | 1.05 |
1.06 |
.94 |
.95 |
1.00 |
.89 |
.89 |
| KLA/ATP | .92 |
.84 |
.87 |
.93 |
.91 |
.92 |
.82 |
|
Mm.46002 4 | |
38348245 |
Unknown |
KLA | 1.22 |
1.25 |
1.25 |
1.19 |
1.22 |
1.47 |
1.14 |
| ATP | 1.03 |
.94 |
1.01 |
1.01 |
2.67 |
2.31 |
1.37 |
| KLA/ATP | 1.35 |
1.19 |
1.27 |
1.22 |
1.99 |
1.83 |
1.45 |
|
Mm.46359 0 | |
21687181 |
Unknown |
KLA | .76 |
.80 |
.87 |
.99 |
.94 |
1.02 |
.98 |
| ATP | .90 |
.94 |
1.06 |
.97 |
.83 |
.93 |
.85 |
| KLA/ATP | .79 |
.91 |
.98 |
1.01 |
.97 |
.84 |
.78 |
|
Mm.5055 | |
145966820 |
Unknown |
KLA | 1.04 |
.96 |
1.04 |
.97 |
1.00 |
1.00 |
.97 |
| ATP | .95 |
.97 |
.96 |
.95 |
.97 |
.97 |
.98 |
| KLA/ATP | .88 |
1.04 |
1.07 |
1.02 |
.97 |
.98 |
.96 |
|
Mm.56965
| |
6679704 |
Unknown |
KLA | .96 |
1.05 |
1.06 |
1.01 |
1.05 |
.99 |
.98 |
| ATP | .95 |
.99 |
.93 |
1.05 |
.97 |
.96 |
1.02 |
| KLA/ATP | .95 |
1.01 |
1.03 |
1.02 |
.98 |
.98 |
.98 |
|
Mm.80682
| |
94369627 |
Unknown |
KLA | .96 |
1.00 |
.97 |
.97 |
1.07 |
1.05 |
.99 |
| ATP | .97 |
1.02 |
.98 |
1.01 |
1.01 |
1.06 |
.96 |
| KLA/ATP | 1.00 |
.93 |
1.02 |
1.08 |
.98 |
.95 |
.97 |
|
Mm.87663
| |
142370454 |
Unknown |
KLA | 1.04 |
1.01 |
1.01 |
1.10 |
.95 |
1.04 |
.95 |
| ATP | .96 |
1.01 |
.96 |
.98 |
.94 |
1.05 |
1.12 |
| KLA/ATP | .98 |
.97 |
1.12 |
1.03 |
1.06 |
.94 |
1.02 |
|
Mos | |
NM_020021 |
Moloney sarcoma oncogene (Mos), mRNA [NM_020021] |
KLA | 1.14 |
1.04 |
1.00 |
.98 |
1.09 |
.94 |
.98 |
| ATP | 1.00 |
1.01 |
1.03 |
1.05 |
.92 |
1.04 |
1.12 |
| KLA/ATP | .97 |
.96 |
1.04 |
1.03 |
.95 |
.99 |
1.03 |
|
Mras | |
NM_008624 |
muscle and microspikes RAS (Mras), mRNA [NM_008624] |
KLA | .77 |
.76 |
.75 |
.84 |
.92 |
.87 |
1.35 |
| ATP | 1.02 |
1.00 |
1.11 |
1.14 |
.87 |
.79 |
.80 |
| KLA/ATP | .77 |
.77 |
.86 |
.78 |
.69 |
.63 |
.61 |
|
Myc | |
NM_010849 |
myelocytomatosis oncogene (Myc), mRNA [NM_010849] |
KLA | .38 |
.31 |
.45 |
.45 |
.49 |
.35 |
.33 |
| ATP | 1.05 |
1.09 |
1.72 |
4.41 |
1.28 |
.45 |
.76 |
| KLA/ATP | .37 |
.30 |
.44 |
1.23 |
.34 |
.17 |
.19 |
|
Nf1 | |
NM_010897 |
neurofibromatosis 1 (Nf1), mRNA [NM_010897] |
KLA | .96 |
1.05 |
.95 |
.91 |
1.05 |
1.02 |
1.04 |
| ATP | .96 |
1.04 |
.97 |
.99 |
.82 |
.86 |
1.31 |
| KLA/ATP | 1.05 |
1.03 |
.88 |
.93 |
.72 |
.79 |
1.28 |
|
Nfatc2 | |
AK081853 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130082H17 product:nuclear factor of activated T-cells, cytoplasmic 2, full insert sequence. [AK081853] |
KLA | .56 |
.52 |
.59 |
.61 |
.78 |
.78 |
.66 |
| ATP | 1.19 |
1.27 |
.67 |
.65 |
.62 |
.53 |
.79 |
| KLA/ATP | .52 |
.49 |
.71 |
.57 |
.65 |
.52 |
.53 |
|
Nfatc2 | |
NM_001037177 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 2, mRNA [NM_001037177] |
KLA | .84 |
.79 |
.74 |
.82 |
.89 |
.98 |
.80 |
| ATP | 1.06 |
1.13 |
1.01 |
.87 |
.86 |
.83 |
1.10 |
| KLA/ATP | .76 |
.72 |
.89 |
.84 |
.84 |
.81 |
.84 |
|
Nfatc2 | |
NM_010899 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 1, mRNA [NM_010899] |
KLA | .90 |
.91 |
.86 |
.91 |
.86 |
1.07 |
1.00 |
| ATP | 1.08 |
1.11 |
1.45 |
1.04 |
.88 |
.85 |
1.18 |
| KLA/ATP | .85 |
.89 |
.92 |
.89 |
.93 |
.84 |
1.13 |
|
Nfatc4 | |
AK014164 |
13 days embryo head cDNA, RIKEN full-length enriched library, clone:3110041H08 product:nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4, full insert sequence. [AK014164] |
KLA | .90 |
.92 |
.91 |
1.00 |
.99 |
.98 |
.95 |
| ATP | .90 |
1.03 |
.96 |
.98 |
.95 |
.97 |
1.00 |
| KLA/ATP | .95 |
.87 |
1.00 |
.98 |
.96 |
.96 |
.92 |
|
Nfatc4 | |
NM_023699 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 (Nfatc4), mRNA [NM_023699] |
KLA | 1.28 |
1.38 |
1.44 |
1.58 |
1.40 |
1.41 |
1.46 |
| ATP | 1.03 |
1.06 |
1.23 |
1.24 |
1.32 |
1.40 |
1.41 |
| KLA/ATP | 1.30 |
1.38 |
1.47 |
1.28 |
1.38 |
1.40 |
1.63 |
|
Nfkb1 | |
BC050841 |
nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] |
KLA | 5.81 |
4.96 |
4.77 |
3.21 |
3.37 |
2.00 |
1.71 |
| ATP | 1.39 |
1.52 |
3.25 |
12.63 |
13.64 |
4.80 |
1.08 |
| KLA/ATP | 7.21 |
8.69 |
19.53 |
23.93 |
11.70 |
2.85 |
2.01 |
|
Nfkb1 | |
M57999 |
gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] |
KLA | 8.55 |
7.87 |
7.35 |
6.13 |
3.51 |
1.85 |
1.38 |
| ATP | .98 |
.96 |
1.21 |
3.06 |
5.29 |
4.67 |
.69 |
| KLA/ATP | 7.32 |
7.20 |
8.71 |
10.82 |
5.55 |
2.77 |
1.54 |
|
Nfkb2 | |
NM_019408 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100 (Nfkb2), mRNA [NM_019408] |
KLA | 7.31 |
7.92 |
7.95 |
6.42 |
6.41 |
4.42 |
2.81 |
| ATP | .99 |
.98 |
.72 |
1.48 |
2.80 |
5.31 |
1.44 |
| KLA/ATP | 8.25 |
7.93 |
6.51 |
7.68 |
5.08 |
4.38 |
4.86 |
|
Ngf | |
NM_013609 |
nerve growth factor (Ngf), transcript variant A, mRNA [NM_013609] |
KLA | .99 |
.98 |
.97 |
.99 |
.97 |
1.10 |
1.05 |
| ATP | .94 |
1.03 |
.99 |
1.00 |
.93 |
1.05 |
1.01 |
| KLA/ATP | .94 |
1.01 |
.99 |
.98 |
.98 |
1.11 |
1.02 |
|
Nlk | |
NM_008702 |
nemo like kinase (Nlk), mRNA [NM_008702] |
KLA | .71 |
.70 |
.64 |
.71 |
.78 |
.95 |
.94 |
| ATP | .91 |
.89 |
.95 |
.70 |
.45 |
.64 |
1.05 |
| KLA/ATP | .61 |
.66 |
.84 |
.54 |
.53 |
.58 |
.79 |
|
Nr4a1 | |
NM_010444 |
nuclear receptor subfamily 4, group A, member 1 (Nr4a1), mRNA [NM_010444] |
KLA | .44 |
.45 |
.47 |
.82 |
.71 |
.50 |
.55 |
| ATP | 11.54 |
20.34 |
46.57 |
49.45 |
32.16 |
7.11 |
.84 |
| KLA/ATP | 4.55 |
17.35 |
51.68 |
56.03 |
42.95 |
13.43 |
2.21 |
|
Nras | |
NM_010937 |
neuroblastoma ras oncogene (Nras), mRNA [NM_010937] |
KLA | 1.20 |
1.22 |
1.27 |
1.20 |
1.09 |
.91 |
.84 |
| ATP | .98 |
.91 |
.69 |
.61 |
.59 |
.67 |
.78 |
| KLA/ATP | 1.22 |
1.14 |
.97 |
.79 |
.73 |
.61 |
.72 |
|
Ntf3 | |
NM_008742 |
neurotrophin 3 (Ntf3), mRNA [NM_008742] |
KLA | 1.08 |
.93 |
1.06 |
1.02 |
1.03 |
1.01 |
.96 |
| ATP | 1.00 |
1.03 |
.96 |
.94 |
.96 |
1.01 |
1.02 |
| KLA/ATP | .95 |
1.00 |
.98 |
1.01 |
.96 |
.94 |
1.02 |
|
Ntf5 | |
NM_198190 |
neurotrophin 5 (Ntf5), mRNA [NM_198190] |
KLA | 1.07 |
1.02 |
.97 |
1.03 |
1.06 |
.98 |
1.03 |
| ATP | 1.00 |
1.05 |
.97 |
.99 |
1.01 |
1.02 |
1.05 |
| KLA/ATP | .98 |
1.00 |
1.10 |
1.02 |
.95 |
.96 |
1.06 |
|
Ntrk1 | |
NM_001033124 |
neurotrophic tyrosine kinase, receptor, type 1 (Ntrk1), mRNA [NM_001033124] |
KLA | .95 |
.96 |
1.03 |
1.03 |
.95 |
1.01 |
1.02 |
| ATP | 1.04 |
.98 |
.98 |
1.07 |
.99 |
1.01 |
1.02 |
| KLA/ATP | .97 |
1.03 |
1.10 |
1.02 |
1.05 |
1.00 |
.97 |
|
Ntrk2 | |
AK018789 |
adult male cerebellum cDNA, RIKEN full-length enriched library, clone:1500040I13 product:neurotrophic tyrosine kinase, receptor, type 2, full insert sequence. [AK018789] |
KLA | 1.02 |
.94 |
1.05 |
1.03 |
1.03 |
1.03 |
1.04 |
| ATP | .99 |
1.01 |
1.09 |
.95 |
1.02 |
.99 |
1.04 |
| KLA/ATP | 1.02 |
.96 |
1.00 |
1.04 |
1.13 |
.99 |
1.03 |
|
Ntrk2 | |
NM_001025074 |
neurotrophic tyrosine kinase, receptor, type 2 (Ntrk2), transcript variant 1, mRNA [NM_001025074] |
KLA | .99 |
.99 |
1.02 |
1.02 |
1.02 |
1.00 |
1.03 |
| ATP | .99 |
.99 |
.99 |
.99 |
1.00 |
1.01 |
1.03 |
| KLA/ATP | .97 |
1.00 |
1.01 |
1.00 |
.99 |
.98 |
1.00 |
|
Ntrk2 | |
NM_008745 |
neurotrophic tyrosine kinase, receptor, type 2 (Ntrk2), transcript variant 2, mRNA [NM_008745] |
KLA | .99 |
1.00 |
.99 |
1.00 |
.99 |
1.00 |
1.02 |
| ATP | 1.01 |
1.00 |
1.01 |
.97 |
1.01 |
1.01 |
.99 |
| KLA/ATP | .99 |
1.01 |
.99 |
1.01 |
.99 |
.99 |
1.01 |
|
Pak1 | |
NM_011035 |
p21 (CDKN1A)-activated kinase 1 (Pak1), mRNA [NM_011035] |
KLA | .72 |
.77 |
.79 |
.71 |
.67 |
.73 |
.95 |
| ATP | 1.10 |
1.07 |
.99 |
1.15 |
1.27 |
.62 |
.51 |
| KLA/ATP | .85 |
.83 |
.73 |
.76 |
.76 |
.55 |
.33 |
|
Pak2 | |
NM_177326 |
p21 (CDKN1A)-activated kinase 2 (Pak2), mRNA [NM_177326] |
KLA | 1.23 |
1.24 |
1.26 |
1.17 |
1.19 |
1.09 |
1.13 |
| ATP | 1.04 |
1.01 |
.65 |
.58 |
.82 |
1.18 |
1.45 |
| KLA/ATP | 1.26 |
1.26 |
.78 |
.72 |
.71 |
.95 |
1.44 |
|
Pdgfa | |
NM_008808 |
platelet derived growth factor, alpha (Pdgfa), mRNA [NM_008808] |
KLA | .63 |
.56 |
.42 |
.34 |
.31 |
.33 |
.52 |
| ATP | .89 |
.80 |
.69 |
1.23 |
5.97 |
3.99 |
2.73 |
| KLA/ATP | .64 |
.53 |
.43 |
.77 |
3.48 |
3.78 |
2.37 |
|
Pdgfb | |
NM_011057 |
platelet derived growth factor, B polypeptide (Pdgfb), mRNA [NM_011057] |
KLA | .45 |
.43 |
.38 |
.46 |
.69 |
.48 |
.58 |
| ATP | .94 |
.95 |
.66 |
.74 |
.67 |
.77 |
1.06 |
| KLA/ATP | .43 |
.43 |
.37 |
.39 |
.52 |
.55 |
1.64 |
|
Pdgfra | |
NM_011058 |
platelet derived growth factor receptor, alpha polypeptide (Pdgfra), transcript variant 1, mRNA [NM_011058] |
KLA | 1.02 |
1.05 |
1.02 |
1.01 |
1.03 |
1.03 |
1.01 |
| ATP | 1.01 |
1.02 |
1.03 |
1.04 |
1.00 |
1.01 |
1.01 |
| KLA/ATP | 1.01 |
1.01 |
.99 |
1.03 |
1.02 |
1.03 |
1.01 |
|
Pdgfrb | |
NM_008809 |
platelet derived growth factor receptor, beta polypeptide (Pdgfrb), mRNA [NM_008809] |
KLA | 4.85 |
5.49 |
4.56 |
3.94 |
3.71 |
2.05 |
1.51 |
| ATP | .99 |
1.00 |
1.11 |
1.27 |
1.02 |
1.83 |
1.23 |
| KLA/ATP | 5.09 |
5.86 |
4.30 |
2.51 |
1.74 |
1.84 |
3.23 |
|
Pla2g4a | |
NM_008869 |
phospholipase A2, group IVA (cytosolic, calcium-dependent) (Pla2g4a), mRNA [NM_008869] |
KLA | 3.93 |
4.49 |
4.86 |
6.40 |
6.44 |
3.10 |
1.68 |
| ATP | 1.13 |
1.36 |
1.27 |
1.30 |
1.02 |
5.37 |
1.47 |
| KLA/ATP | 3.64 |
4.45 |
4.76 |
7.11 |
2.96 |
4.08 |
2.60 |
|
Pla2g4b | |
NM_145378 |
phospholipase A2, group IVB (cytosolic) (Pla2g4b), mRNA [NM_145378] |
KLA | 1.09 |
1.18 |
.95 |
1.01 |
.97 |
.97 |
.77 |
| ATP | 1.05 |
1.14 |
1.28 |
.94 |
.88 |
1.18 |
.70 |
| KLA/ATP | 1.23 |
1.43 |
1.21 |
1.02 |
1.15 |
1.16 |
.78 |
|
Pla2g4c | |
AK145339 |
1 cell embryo 1 cell cDNA, RIKEN full-length enriched library, clone:I0C0013F18 product:weakly similar to Cytosolic phospholipase A2 gamma [Homo sapiens], full insert sequence [AK145339] |
KLA | 1.09 |
1.21 |
1.33 |
1.17 |
1.26 |
1.30 |
1.05 |
| ATP | .97 |
1.06 |
1.00 |
.98 |
.98 |
.98 |
1.05 |
| KLA/ATP | 1.19 |
1.16 |
1.18 |
1.13 |
1.04 |
1.02 |
1.06 |
|
Pla2g4c | |
NM_001004762 |
phospholipase A2, group IVC (cytosolic, calcium-independent) (Pla2g4c), mRNA [NM_001004762] |
KLA | .93 |
1.00 |
.94 |
.93 |
.94 |
.94 |
.96 |
| ATP | .98 |
.96 |
1.13 |
.97 |
.99 |
.89 |
.96 |
| KLA/ATP | 1.01 |
1.01 |
1.07 |
1.01 |
.94 |
1.01 |
.92 |
|
Pla2g4e | |
AK049063 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230096D22 product:hypothetical Lysophospholipase catalytic domain containing protein, full insert sequence. [AK049063] |
KLA | 1.03 |
1.09 |
1.01 |
1.01 |
1.06 |
.94 |
1.05 |
| ATP | 1.03 |
1.00 |
1.06 |
1.01 |
.96 |
1.05 |
1.05 |
| KLA/ATP | .98 |
1.00 |
1.01 |
.98 |
1.03 |
.95 |
1.01 |
|
Pla2g4e | |
NM_177845 |
phospholipase A2, group IVE (Pla2g4e), mRNA [NM_177845] |
KLA | .97 |
.95 |
1.01 |
.97 |
1.02 |
1.03 |
1.05 |
| ATP | .98 |
.99 |
1.00 |
1.10 |
.98 |
1.00 |
1.02 |
| KLA/ATP | 1.05 |
.93 |
.96 |
1.03 |
1.08 |
1.05 |
.99 |
|
Pla2g4f | |
NM_001024145 |
phospholipase A2, group IVF (Pla2g4f), mRNA [NM_001024145] |
KLA | 1.08 |
.99 |
1.04 |
1.02 |
1.04 |
.98 |
1.01 |
| ATP | .99 |
1.04 |
.99 |
1.03 |
1.12 |
1.01 |
1.25 |
| KLA/ATP | .97 |
1.04 |
1.10 |
1.06 |
1.04 |
1.03 |
1.03 |
|
Ppm1a | |
AF369981 |
PP alpha 2 mRNA, complete cds [AF369981] |
KLA | 1.37 |
1.28 |
1.19 |
1.18 |
1.04 |
.95 |
1.26 |
| ATP | 1.06 |
1.04 |
1.25 |
.86 |
1.05 |
1.19 |
1.13 |
| KLA/ATP | 1.50 |
1.39 |
1.29 |
.90 |
.94 |
.77 |
.83 |
|
Ppm1a | |
NM_008910 |
protein phosphatase 1A, magnesium dependent, alpha isoform (Ppm1a), mRNA [NM_008910] |
KLA | 1.12 |
1.12 |
1.11 |
.92 |
.96 |
.91 |
1.15 |
| ATP | 1.04 |
1.07 |
.94 |
.97 |
1.28 |
1.56 |
1.07 |
| KLA/ATP | 1.09 |
1.14 |
.95 |
1.02 |
1.17 |
1.41 |
1.34 |
|
Ppm1b | |
BC090963 |
protein phosphatase 1B, magnesium dependent, beta isoform, mRNA (cDNA clone MGC:106489 IMAGE:30632168), complete cds. [BC090963] |
KLA | 1.44 |
1.37 |
1.24 |
1.09 |
1.02 |
.84 |
1.36 |
| ATP | 1.27 |
1.33 |
1.25 |
.97 |
.77 |
.47 |
.58 |
| KLA/ATP | 1.42 |
1.59 |
1.60 |
1.20 |
.75 |
.30 |
.43 |
|
Ppm1b | |
NM_011151 |
protein phosphatase 1B, magnesium dependent, beta isoform (Ppm1b), mRNA [NM_011151] |
KLA | 1.91 |
1.87 |
1.82 |
1.60 |
1.43 |
1.18 |
1.21 |
| ATP | .98 |
.99 |
.96 |
1.03 |
1.28 |
1.55 |
.87 |
| KLA/ATP | 1.79 |
1.98 |
1.86 |
1.73 |
1.68 |
1.52 |
1.05 |
|
Ppp3ca | |
NM_008913 |
protein phosphatase 3, catalytic subunit, alpha isoform (Ppp3ca), mRNA [NM_008913] |
KLA | .76 |
.85 |
.81 |
.85 |
.73 |
.70 |
.52 |
| ATP | .96 |
.78 |
.55 |
.46 |
.31 |
.33 |
.48 |
| KLA/ATP | .74 |
.64 |
.52 |
.42 |
.37 |
.36 |
.45 |
|
Ppp3cb | |
AK135203 |
12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-length enriched library, clone:6720421K10 product:protein phosphatase 3, catalytic subunit, beta isoform, full insert sequence. [AK135203] |
KLA | 1.74 |
1.57 |
1.91 |
1.59 |
1.47 |
1.26 |
1.40 |
| ATP | 1.17 |
1.03 |
1.30 |
1.00 |
.81 |
.62 |
1.37 |
| KLA/ATP | 1.68 |
1.70 |
1.91 |
1.37 |
1.09 |
.47 |
1.13 |
|
Ppp3cb | |
AK171904 |
activated spleen cDNA, RIKEN full-length enriched library, clone:F830018L06 product:Protein phosphatase 3 catalytic subunit beta3 (EC 3.1.3.16) (Serine [AK171904] |
KLA | 1.29 |
1.29 |
1.21 |
1.15 |
1.22 |
1.13 |
1.28 |
| ATP | .90 |
.86 |
.80 |
.98 |
.94 |
.73 |
.92 |
| KLA/ATP | 1.06 |
1.03 |
.77 |
1.04 |
.92 |
.68 |
.90 |
|
Ppp3cb | |
NM_008914 |
protein phosphatase 3, catalytic subunit, beta isoform (Ppp3cb), mRNA [NM_008914] |
KLA | 1.21 |
1.29 |
1.38 |
1.24 |
1.29 |
1.08 |
1.23 |
| ATP | 1.15 |
1.31 |
1.09 |
1.29 |
.86 |
.60 |
.64 |
| KLA/ATP | 1.33 |
1.40 |
1.04 |
1.28 |
.79 |
.58 |
.73 |
|
Ppp3cc | |
AK037563 |
16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026K22 product:unclassifiable, full insert sequence [AK037563] |
KLA | 1.27 |
1.18 |
1.21 |
1.15 |
1.01 |
.92 |
1.36 |
| ATP | .96 |
1.09 |
1.10 |
1.03 |
.85 |
1.06 |
1.47 |
| KLA/ATP | 1.17 |
1.24 |
1.07 |
1.13 |
.91 |
.88 |
1.36 |
|
Ppp3cc | |
NM_008915 |
protein phosphatase 3, catalytic subunit, gamma isoform (Ppp3cc), mRNA [NM_008915] |
KLA | 1.64 |
1.81 |
1.79 |
1.35 |
.90 |
.70 |
1.31 |
| ATP | .90 |
.90 |
1.13 |
.93 |
.86 |
1.40 |
1.60 |
| KLA/ATP | 1.45 |
1.62 |
1.74 |
1.47 |
1.04 |
1.01 |
1.31 |
|
Ppp3r1 | |
NM_024459 |
protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) (Ppp3r1), mRNA [NM_024459] |
KLA | 1.02 |
1.17 |
.93 |
1.27 |
1.15 |
1.30 |
1.30 |
| ATP | .97 |
.95 |
.77 |
.91 |
.99 |
1.18 |
1.10 |
| KLA/ATP | 1.12 |
1.04 |
.88 |
1.00 |
1.10 |
1.10 |
1.07 |
|
Ppp3r2 | |
NM_001004025 |
protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type II) (Ppp3r2), mRNA [NM_001004025] |
KLA | 1.03 |
1.05 |
1.06 |
1.08 |
1.12 |
1.05 |
1.04 |
| ATP | 1.00 |
1.02 |
1.04 |
1.04 |
.99 |
.99 |
1.01 |
| KLA/ATP | 1.04 |
1.12 |
1.03 |
1.09 |
1.00 |
.99 |
1.00 |
|
Ppp5c | |
NM_011155 |
protein phosphatase 5, catalytic subunit (Ppp5c), mRNA [NM_011155] |
KLA | .85 |
.80 |
.89 |
.80 |
.90 |
1.05 |
1.20 |
| ATP | 1.00 |
1.07 |
.99 |
1.15 |
1.16 |
.97 |
.88 |
| KLA/ATP | .86 |
.86 |
.78 |
.91 |
.93 |
.97 |
.78 |
|
Prkaca | |
NM_008854 |
protein kinase, cAMP dependent, catalytic, alpha (Prkaca), mRNA [NM_008854] |
KLA | .71 |
.74 |
.72 |
.70 |
.72 |
.84 |
.85 |
| ATP | 1.05 |
.98 |
.89 |
.92 |
.76 |
.60 |
1.02 |
| KLA/ATP | .79 |
.74 |
.55 |
.65 |
.60 |
.65 |
.93 |
|
Prkacb | |
NM_011100 |
protein kinase, cAMP dependent, catalytic, beta (Prkacb), mRNA [NM_011100] |
KLA | .69 |
.70 |
.66 |
.58 |
.51 |
.55 |
.59 |
| ATP | 1.02 |
1.19 |
.97 |
1.01 |
.69 |
.38 |
.56 |
| KLA/ATP | .72 |
.73 |
.57 |
.62 |
.47 |
.41 |
.45 |
|
Prkca | |
NM_011101 |
protein kinase C, alpha (Prkca), mRNA [NM_011101] |
KLA | 1.00 |
.96 |
.94 |
.95 |
.95 |
.89 |
.96 |
| ATP | 1.00 |
1.03 |
.91 |
.94 |
.82 |
.87 |
1.13 |
| KLA/ATP | 1.02 |
.95 |
.91 |
.86 |
.78 |
.84 |
.94 |
|
Prkcb1 | |
NM_008855 |
protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] |
KLA | .92 |
.95 |
.93 |
.78 |
.77 |
1.08 |
1.83 |
| ATP | 1.03 |
1.12 |
1.09 |
1.23 |
.90 |
2.08 |
.96 |
| KLA/ATP | .98 |
.99 |
.82 |
.89 |
.62 |
1.01 |
1.08 |
|
Prkcc | |
NM_011102 |
protein kinase C, gamma (Prkcc), mRNA [NM_011102] |
KLA | 1.02 |
1.04 |
1.11 |
1.04 |
.96 |
1.02 |
1.05 |
| ATP | .98 |
.98 |
1.05 |
1.03 |
1.08 |
.96 |
.95 |
| KLA/ATP | 1.21 |
1.16 |
1.09 |
1.07 |
1.04 |
.98 |
.93 |
|
Prkx | |
NM_016979 |
protein kinase, X-linked (Prkx), mRNA [NM_016979] |
KLA | 3.61 |
3.79 |
4.67 |
4.66 |
4.85 |
4.19 |
1.43 |
| ATP | .98 |
.90 |
.63 |
.61 |
1.12 |
1.90 |
1.29 |
| KLA/ATP | 3.56 |
3.36 |
2.62 |
2.06 |
2.26 |
2.87 |
2.31 |
|
Ptpn5 | |
NM_013643 |
protein tyrosine phosphatase, non-receptor type 5 (Ptpn5), mRNA [NM_013643] |
KLA | 1.16 |
1.20 |
1.25 |
1.15 |
1.23 |
1.13 |
1.16 |
| ATP | .96 |
1.13 |
1.54 |
2.10 |
1.88 |
1.28 |
1.02 |
| KLA/ATP | 1.12 |
1.12 |
2.12 |
1.93 |
2.07 |
1.59 |
1.30 |
|
Ptpn7 | |
NM_177081 |
protein tyrosine phosphatase, non-receptor type 7 (Ptpn7), mRNA [NM_177081] |
KLA | .31 |
.31 |
.35 |
.43 |
.68 |
.86 |
.77 |
| ATP | .97 |
1.06 |
.86 |
.82 |
.50 |
.68 |
.92 |
| KLA/ATP | .33 |
.30 |
.31 |
.34 |
.34 |
.51 |
.79 |
|
Ptprr | |
AK051719 |
12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130067J21 product:protein tyrosine phosphatase, receptor type, R, full insert sequence. [AK051719] |
KLA | .99 |
.98 |
.95 |
1.00 |
.99 |
.95 |
.95 |
| ATP | 1.03 |
.98 |
.97 |
1.03 |
.92 |
1.07 |
1.01 |
| KLA/ATP | .98 |
1.02 |
1.06 |
.96 |
.99 |
.95 |
1.02 |
|
Ptprr | |
NM_011217 |
protein tyrosine phosphatase, receptor type, R (Ptprr), mRNA [NM_011217] |
KLA | .97 |
1.04 |
1.00 |
.96 |
.99 |
.98 |
1.02 |
| ATP | .96 |
1.02 |
.96 |
.98 |
.99 |
.98 |
.98 |
| KLA/ATP | .98 |
1.04 |
1.02 |
1.01 |
.95 |
.96 |
1.00 |
|
Rac1 | |
NM_009007 |
RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] |
KLA | 1.02 |
1.01 |
1.02 |
.99 |
1.03 |
1.15 |
1.08 |
| ATP | .99 |
1.15 |
1.01 |
1.27 |
1.06 |
1.20 |
1.06 |
| KLA/ATP | 1.00 |
1.04 |
.88 |
1.16 |
.91 |
1.21 |
1.38 |
|
Rac2 | |
NM_009008 |
RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] |
KLA | 1.55 |
1.68 |
1.86 |
2.15 |
3.36 |
3.59 |
3.74 |
| ATP | 1.13 |
1.16 |
.74 |
.99 |
.84 |
.91 |
1.66 |
| KLA/ATP | 1.59 |
1.71 |
1.19 |
1.56 |
1.21 |
1.60 |
3.48 |
|
Rac3 | |
NM_133223 |
RAS-related C3 botulinum substrate 3 (Rac3), mRNA [NM_133223] |
KLA | 2.03 |
2.20 |
2.64 |
2.18 |
2.95 |
2.29 |
1.41 |
| ATP | 1.02 |
1.12 |
.94 |
1.42 |
1.16 |
.84 |
.87 |
| KLA/ATP | 2.30 |
2.32 |
1.57 |
2.55 |
1.75 |
1.47 |
1.61 |
|
Raf1 | |
AK036317 |
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] |
KLA | 1.47 |
1.34 |
1.55 |
1.29 |
1.59 |
1.32 |
1.46 |
| ATP | 1.05 |
.98 |
.54 |
.63 |
3.32 |
2.07 |
1.01 |
| KLA/ATP | 1.57 |
1.33 |
.79 |
.96 |
2.26 |
1.38 |
1.35 |
|
Raf1 | |
NM_029780 |
v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] |
KLA | 1.65 |
1.64 |
1.93 |
1.77 |
1.77 |
1.72 |
1.81 |
| ATP | .95 |
.96 |
.83 |
.80 |
2.22 |
2.92 |
1.19 |
| KLA/ATP | 1.68 |
1.64 |
1.39 |
1.32 |
1.85 |
2.50 |
2.06 |
|
Rap1a | |
AK030897 |
adult male thymus cDNA, RIKEN full-length enriched library, clone:5830450G12 product:RAS-related protein-1a, full insert sequence [AK030897] |
KLA | .83 |
.80 |
.92 |
1.04 |
1.06 |
.91 |
1.06 |
| ATP | 1.04 |
.92 |
1.11 |
1.03 |
1.05 |
.73 |
.72 |
| KLA/ATP | .83 |
.81 |
.97 |
.75 |
1.14 |
.71 |
.53 |
|
Rap1a | |
NM_145541 |
RAS-related protein-1a (Rap1a), mRNA [NM_145541] |
KLA | .87 |
.78 |
.76 |
.86 |
.86 |
.84 |
1.01 |
| ATP | .91 |
.95 |
1.33 |
1.20 |
1.27 |
1.04 |
.81 |
| KLA/ATP | .68 |
.75 |
.92 |
.85 |
1.13 |
.90 |
.74 |
|
Rap1b | |
M79314 |
GTP-binding protein RAP1b mRNA, partial cds. [M79314] |
KLA | 2.61 |
2.95 |
2.81 |
2.76 |
3.07 |
2.67 |
1.88 |
| ATP | 1.00 |
1.10 |
1.00 |
1.94 |
1.94 |
1.72 |
1.31 |
| KLA/ATP | 2.49 |
2.45 |
2.03 |
4.23 |
3.03 |
2.60 |
1.86 |
|
Rap1b | |
NM_024457 |
RAS related protein 1b (Rap1b), mRNA [NM_024457] |
KLA | 2.21 |
2.35 |
2.71 |
2.51 |
2.86 |
2.44 |
1.54 |
| ATP | 1.05 |
.92 |
.93 |
1.14 |
1.30 |
1.26 |
1.07 |
| KLA/ATP | 2.23 |
2.15 |
1.57 |
2.53 |
2.16 |
1.67 |
1.38 |
|
Rapgef2 | |
AK037061 |
adult female vagina cDNA, RIKEN full-length enriched library, clone:9930105G09 product:unclassifiable, full insert sequence. [AK037061] |
KLA | 2.39 |
1.88 |
1.69 |
1.79 |
1.91 |
1.73 |
1.42 |
| ATP | 1.10 |
1.22 |
1.29 |
1.61 |
1.28 |
1.41 |
1.15 |
| KLA/ATP | 2.62 |
3.19 |
3.35 |
1.61 |
1.35 |
1.67 |
2.05 |
|
Rapgef2 | |
NM_001099624 |
Rap guanine nucleotide exchange factor (GEF) 2 (Rapgef2), mRNA [NM_001099624] |
KLA | 13.96 |
13.30 |
14.47 |
15.36 |
15.40 |
13.03 |
6.27 |
| ATP | .92 |
.91 |
1.07 |
6.35 |
8.30 |
6.34 |
4.39 |
| KLA/ATP | 13.04 |
12.81 |
13.27 |
19.07 |
15.46 |
12.66 |
20.32 |
|
Rasa1 | |
AK042801 |
7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730025L23 product:unclassifiable, full insert sequence. [AK042801] |
KLA | .85 |
.88 |
.86 |
.82 |
.86 |
.85 |
.92 |
| ATP | 1.05 |
.95 |
.85 |
.80 |
.81 |
.82 |
.95 |
| KLA/ATP | .94 |
.88 |
.87 |
.85 |
.86 |
.83 |
.91 |
|
Rasa1 | |
NM_145452 |
RAS p21 protein activator 1 (Rasa1), mRNA [NM_145452] |
KLA | .37 |
.38 |
.36 |
.36 |
.33 |
.35 |
.57 |
| ATP | .96 |
.88 |
.54 |
.42 |
.23 |
.23 |
.70 |
| KLA/ATP | .36 |
.35 |
.23 |
.25 |
.23 |
.23 |
.44 |
|
Rasa2 | |
AK081420 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130016C09 product:unclassifiable, full insert sequence. [AK081420] |
KLA | 1.12 |
1.06 |
1.09 |
1.04 |
.92 |
.91 |
1.19 |
| ATP | 1.34 |
1.69 |
2.20 |
1.41 |
1.41 |
.97 |
.97 |
| KLA/ATP | 1.10 |
1.18 |
1.48 |
1.09 |
1.02 |
.91 |
.86 |
|
Rasa2 | |
NM_053268 |
RAS p21 protein activator 2 (Rasa2), mRNA [NM_053268] |
KLA | 1.28 |
1.22 |
.92 |
.86 |
.96 |
.93 |
1.50 |
| ATP | 1.10 |
1.23 |
.93 |
.92 |
3.23 |
1.69 |
1.61 |
| KLA/ATP | 1.40 |
1.43 |
.87 |
.95 |
1.61 |
1.12 |
1.50 |
|
Rasgrf1 | |
BC042449 |
RAS protein-specific guanine nucleotide-releasing factor 1, mRNA (cDNA clone IMAGE:5367388), complete cds. [BC042449] |
KLA | 1.11 |
1.11 |
1.10 |
1.14 |
1.10 |
1.07 |
1.16 |
| ATP | 1.03 |
1.14 |
1.26 |
1.35 |
1.09 |
1.10 |
1.01 |
| KLA/ATP | 1.12 |
1.14 |
1.13 |
1.15 |
.99 |
1.04 |
1.43 |
|
Rasgrf1 | |
NM_001039655 |
RAS protein-specific guanine nucleotide-releasing factor 1 (Rasgrf1), transcript variant 2, mRNA [NM_001039655] |
KLA | 1.26 |
1.28 |
1.28 |
1.29 |
1.34 |
1.26 |
1.47 |
| ATP | 1.03 |
1.04 |
1.05 |
.92 |
.98 |
1.18 |
1.22 |
| KLA/ATP | 1.33 |
1.38 |
1.28 |
1.18 |
1.07 |
1.18 |
2.74 |
|
Rasgrf1 | |
NM_011245 |
RAS protein-specific guanine nucleotide-releasing factor 1 (Rasgrf1), transcript variant 1, mRNA [NM_011245] |
KLA | 1.02 |
1.05 |
1.14 |
1.06 |
1.14 |
1.11 |
1.08 |
| ATP | 1.03 |
.99 |
1.00 |
.91 |
.94 |
.99 |
1.01 |
| KLA/ATP | 1.03 |
1.00 |
1.14 |
1.13 |
.98 |
1.01 |
1.53 |
|
Rasgrf2 | |
NM_009027 |
RAS protein-specific guanine nucleotide-releasing factor 2 (Rasgrf2), mRNA [NM_009027] |
KLA | .98 |
.93 |
1.03 |
.96 |
.92 |
.97 |
.98 |
| ATP | 1.06 |
.97 |
.99 |
1.00 |
1.01 |
.94 |
.91 |
| KLA/ATP | .96 |
.95 |
.94 |
.90 |
.98 |
.94 |
.96 |
|
Rasgrp1 | |
NM_011246 |
RAS guanyl releasing protein 1 (Rasgrp1), mRNA [NM_011246] |
KLA | 6.54 |
6.48 |
7.17 |
6.75 |
10.11 |
12.90 |
17.38 |
| ATP | 1.18 |
1.35 |
1.31 |
1.32 |
1.76 |
2.47 |
1.30 |
| KLA/ATP | 5.86 |
7.13 |
6.00 |
5.09 |
3.36 |
5.58 |
14.25 |
|
Rasgrp2 | |
NM_011242 |
RAS, guanyl releasing protein 2 (Rasgrp2), mRNA [NM_011242] |
KLA | .99 |
1.04 |
1.01 |
.96 |
1.02 |
1.07 |
1.09 |
| ATP | .94 |
1.02 |
.98 |
1.08 |
1.02 |
1.04 |
1.00 |
| KLA/ATP | 1.01 |
1.04 |
.96 |
1.06 |
1.05 |
1.06 |
.96 |
|
Rasgrp3 | |
NM_207246 |
RAS, guanyl releasing protein 3 (Rasgrp3), mRNA [NM_207246] |
KLA | .13 |
.11 |
.11 |
.12 |
.10 |
.07 |
.05 |
| ATP | .82 |
.71 |
1.08 |
.69 |
.32 |
.09 |
.12 |
| KLA/ATP | .12 |
.12 |
.17 |
.16 |
.15 |
.09 |
.08 |
|
Rasgrp4 | |
NM_145149 |
RAS guanyl releasing protein 4 (Rasgrp4), mRNA [NM_145149] |
KLA | .90 |
.83 |
.78 |
.90 |
.81 |
.61 |
.51 |
| ATP | 1.10 |
1.18 |
1.10 |
1.22 |
1.03 |
.66 |
.57 |
| KLA/ATP | .88 |
.92 |
.85 |
.98 |
.89 |
.69 |
.70 |
|
Rela | |
NM_009045 |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] |
KLA | 2.05 |
2.05 |
2.07 |
1.75 |
1.83 |
1.58 |
1.33 |
| ATP | 1.03 |
1.08 |
1.10 |
1.44 |
1.61 |
2.48 |
1.05 |
| KLA/ATP | 2.17 |
2.27 |
2.05 |
2.47 |
1.93 |
2.35 |
2.02 |
|
Relb | |
NM_009046 |
avian reticuloendotheliosis viral (v-rel) oncogene related B (Relb), mRNA [NM_009046] |
KLA | 4.39 |
4.46 |
3.54 |
3.47 |
4.36 |
3.18 |
2.72 |
| ATP | 1.01 |
1.07 |
1.23 |
2.66 |
3.23 |
3.50 |
1.24 |
| KLA/ATP | 4.43 |
4.52 |
3.56 |
4.10 |
2.85 |
2.92 |
3.30 |
|
Rps6ka1 | |
NM_009097 |
ribosomal protein S6 kinase polypeptide 1 (Rps6ka1), mRNA [NM_009097] |
KLA | .64 |
.65 |
.58 |
.62 |
.78 |
.94 |
.98 |
| ATP | .87 |
.85 |
.78 |
.74 |
.58 |
.68 |
.82 |
| KLA/ATP | .59 |
.52 |
.55 |
.50 |
.50 |
.63 |
.77 |
|
Rps6ka2 | |
NM_011299 |
ribosomal protein S6 kinase, polypeptide 2 (Rps6ka2), mRNA [NM_011299] |
KLA | 1.67 |
1.69 |
1.70 |
1.29 |
1.50 |
1.32 |
1.40 |
| ATP | 1.02 |
1.02 |
.99 |
1.28 |
3.97 |
3.73 |
1.32 |
| KLA/ATP | 1.90 |
1.63 |
1.74 |
1.99 |
2.45 |
2.84 |
1.59 |
|
Rps6ka3 | |
NM_148945 |
ribosomal protein S6 kinase polypeptide 3 (Rps6ka3), mRNA [NM_148945] |
KLA | 2.00 |
2.37 |
2.65 |
2.59 |
2.40 |
1.41 |
.96 |
| ATP | 1.09 |
1.09 |
1.17 |
1.29 |
1.11 |
1.63 |
1.83 |
| KLA/ATP | 2.44 |
2.44 |
2.63 |
3.13 |
1.99 |
1.66 |
2.09 |
|
Rps6ka4 | |
NM_019924 |
ribosomal protein S6 kinase, polypeptide 4 (Rps6ka4), mRNA [NM_019924] |
KLA | 1.23 |
1.21 |
1.39 |
1.13 |
1.53 |
1.38 |
1.49 |
| ATP | 1.23 |
1.29 |
.83 |
1.24 |
1.10 |
1.02 |
.95 |
| KLA/ATP | 1.45 |
1.61 |
.92 |
1.70 |
1.25 |
1.07 |
1.25 |
|
Rps6ka5 | |
NM_153587 |
ribosomal protein S6 kinase, polypeptide 5 (Rps6ka5), mRNA [NM_153587] |
KLA | .79 |
.69 |
.61 |
.60 |
.48 |
.52 |
.49 |
| ATP | 1.14 |
1.25 |
1.29 |
1.14 |
.77 |
.70 |
.56 |
| KLA/ATP | .82 |
.73 |
.65 |
.72 |
.53 |
.59 |
.52 |
|
Rps6ka6 | |
NM_025949 |
ribosomal protein S6 kinase polypeptide 6 (Rps6ka6), mRNA [NM_025949] |
KLA | .98 |
1.03 |
1.06 |
.99 |
1.01 |
1.06 |
1.01 |
| ATP | .96 |
1.00 |
.97 |
.92 |
1.06 |
1.01 |
1.00 |
| KLA/ATP | .95 |
1.01 |
1.01 |
.97 |
1.00 |
.95 |
1.00 |
|
Rras | |
NM_009101 |
Harvey rat sarcoma oncogene, subgroup R (Rras), mRNA [NM_009101] |
KLA | .89 |
.89 |
.99 |
.98 |
1.25 |
1.48 |
1.81 |
| ATP | 1.14 |
1.17 |
1.01 |
1.61 |
1.37 |
1.33 |
1.40 |
| KLA/ATP | 1.09 |
1.05 |
1.01 |
1.34 |
1.24 |
1.10 |
1.27 |
|
Rras2 | |
NM_025846 |
related RAS viral (r-ras) oncogene homolog 2 (Rras2), mRNA [NM_025846] |
KLA | 7.72 |
7.35 |
7.03 |
5.47 |
3.21 |
1.03 |
.65 |
| ATP | .92 |
.86 |
.99 |
.95 |
1.86 |
2.13 |
.72 |
| KLA/ATP | 6.51 |
6.50 |
5.94 |
4.45 |
3.05 |
1.72 |
.75 |
|
Sos1 | |
NM_009231 |
Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] |
KLA | 2.36 |
2.40 |
3.42 |
3.15 |
2.78 |
1.81 |
1.71 |
| ATP | .99 |
1.00 |
.99 |
1.15 |
1.14 |
1.25 |
1.24 |
| KLA/ATP | 2.41 |
2.26 |
1.95 |
2.44 |
1.47 |
1.66 |
1.37 |
|
Sos2 | |
XM_127051 |
gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] |
KLA | .81 |
.77 |
.79 |
.92 |
1.04 |
1.06 |
1.20 |
| ATP | 1.00 |
1.00 |
1.09 |
.79 |
.68 |
.81 |
.94 |
| KLA/ATP | .77 |
.69 |
.71 |
.60 |
.64 |
.77 |
1.07 |
|
Srf | |
NM_020493 |
serum response factor (Srf), mRNA [NM_020493] |
KLA | .56 |
.53 |
.61 |
.82 |
1.37 |
1.04 |
.70 |
| ATP | 1.13 |
.88 |
.71 |
.68 |
.86 |
.85 |
.50 |
| KLA/ATP | .61 |
.51 |
.46 |
.42 |
.82 |
.99 |
.47 |
|
Stk3 | |
AK021111 |
adult male corpus striatum cDNA, RIKEN full-length enriched library, clone:C030030N07 product:unclassifiable, full insert sequence. [AK021111] |
KLA | .94 |
.92 |
1.00 |
.98 |
.97 |
.88 |
1.00 |
| ATP | .84 |
.91 |
.90 |
.83 |
.95 |
.94 |
.92 |
| KLA/ATP | .97 |
.92 |
.88 |
.86 |
.84 |
.85 |
.83 |
|
Stk3 | |
NM_019635 |
serine/threonine kinase 3 (Ste20, yeast homolog) (Stk3), mRNA [NM_019635] |
KLA | 1.51 |
1.51 |
1.59 |
1.55 |
1.42 |
1.23 |
1.14 |
| ATP | .99 |
1.19 |
1.00 |
1.28 |
.82 |
1.41 |
1.01 |
| KLA/ATP | 1.42 |
1.63 |
1.24 |
1.61 |
.90 |
1.13 |
.93 |
|
Stk4 | |
NM_021420 |
serine/threonine kinase 4 (Stk4), mRNA [NM_021420] |
KLA | 2.16 |
2.04 |
1.77 |
1.64 |
1.71 |
1.70 |
1.37 |
| ATP | 1.04 |
1.05 |
.96 |
.91 |
.93 |
1.17 |
1.53 |
| KLA/ATP | 2.08 |
2.13 |
1.73 |
1.59 |
1.25 |
1.35 |
1.88 |
|
Stmn1 | |
NM_019641 |
stathmin 1 (Stmn1), mRNA [NM_019641] |
KLA | .69 |
.73 |
.67 |
.59 |
.50 |
.28 |
.13 |
| ATP | 1.04 |
1.00 |
1.12 |
1.23 |
1.10 |
.62 |
.19 |
| KLA/ATP | .67 |
.70 |
.88 |
.81 |
.74 |
.44 |
.19 |
|
Taok1 | |
NM_144825 |
TAO kinase 1 (Taok1), mRNA [NM_144825] |
KLA | 1.51 |
1.38 |
1.34 |
1.47 |
1.58 |
1.39 |
1.24 |
| ATP | 1.06 |
.97 |
.83 |
.63 |
1.32 |
1.77 |
1.07 |
| KLA/ATP | 1.39 |
1.37 |
1.21 |
.90 |
1.30 |
1.57 |
1.56 |
|
Taok2 | |
AK046145 |
adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230344N16 product:unknown EST, full insert sequence. [AK046145] |
KLA | 1.29 |
1.22 |
1.28 |
1.29 |
1.36 |
1.35 |
1.19 |
| ATP | 1.01 |
1.09 |
1.18 |
1.06 |
1.11 |
1.32 |
1.20 |
| KLA/ATP | 1.14 |
1.21 |
1.41 |
1.31 |
1.21 |
1.16 |
1.40 |
|
Taok2 | |
AK129235 |
mRNA for mKIAA0881 protein. [AK129235] |
KLA | 1.22 |
1.04 |
1.15 |
1.16 |
1.19 |
1.28 |
.84 |
| ATP | 1.03 |
.79 |
.76 |
.46 |
.69 |
.99 |
.64 |
| KLA/ATP | 1.19 |
1.13 |
1.31 |
.78 |
1.12 |
1.07 |
.88 |
|
Taok2 | |
BC085152 |
TAO kinase 2, mRNA (cDNA clone IMAGE:6837633), with apparent retained intron [BC085152] |
KLA | 1.01 |
1.04 |
1.03 |
.92 |
1.02 |
1.13 |
1.04 |
| ATP | .94 |
.91 |
.80 |
.97 |
.99 |
1.30 |
.94 |
| KLA/ATP | 1.07 |
.97 |
1.00 |
1.07 |
1.44 |
1.80 |
1.15 |
|
Taok3 | |
AK037817 |
16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130052D22 product:unclassifiable, full insert sequence. [AK037817] |
KLA | 1.87 |
1.57 |
1.28 |
1.38 |
2.04 |
1.49 |
.95 |
| ATP | 1.13 |
1.52 |
1.02 |
.98 |
.74 |
.94 |
.92 |
| KLA/ATP | 1.81 |
2.50 |
2.06 |
1.84 |
1.09 |
1.10 |
1.28 |
|
Taok3 | |
NM_001081308 |
TAO kinase 3 (Taok3), mRNA [NM_001081308] |
KLA | 1.26 |
1.31 |
1.39 |
1.95 |
1.79 |
1.71 |
.97 |
| ATP | .89 |
.76 |
.56 |
.46 |
.38 |
.56 |
1.01 |
| KLA/ATP | 1.15 |
1.09 |
1.03 |
.81 |
.76 |
.72 |
1.23 |
|
Tgfb1 | |
NM_011577 |
transforming growth factor, beta 1 (Tgfb1), mRNA [NM_011577] |
KLA | .87 |
.89 |
.90 |
.70 |
.83 |
.77 |
1.12 |
| ATP | 1.20 |
1.41 |
.80 |
1.49 |
1.11 |
.93 |
.99 |
| KLA/ATP | 1.10 |
1.20 |
.53 |
1.05 |
.66 |
.85 |
.90 |
|
Tgfb2 | |
NM_009367 |
transforming growth factor, beta 2 (Tgfb2), mRNA [NM_009367] |
KLA | 1.01 |
.91 |
.98 |
.98 |
.92 |
1.19 |
.96 |
| ATP | .99 |
1.03 |
1.00 |
1.02 |
.99 |
1.07 |
.93 |
| KLA/ATP | 1.02 |
.99 |
1.03 |
.98 |
1.04 |
1.06 |
.96 |
|
Tgfb3 | |
NM_009368 |
transforming growth factor, beta 3 (Tgfb3), mRNA [NM_009368] |
KLA | .67 |
.64 |
.58 |
.56 |
.49 |
.52 |
.61 |
| ATP | .90 |
.92 |
1.33 |
1.08 |
.78 |
.65 |
.74 |
| KLA/ATP | .58 |
.60 |
.74 |
.61 |
.76 |
1.36 |
1.51 |
|
Tgfbr1 | |
NM_009370 |
transforming growth factor, beta receptor I (Tgfbr1), mRNA [NM_009370] |
KLA | .73 |
.74 |
.59 |
.54 |
.52 |
.64 |
.84 |
| ATP | .99 |
1.12 |
.99 |
1.16 |
1.22 |
.84 |
.93 |
| KLA/ATP | .75 |
.78 |
.58 |
.64 |
.62 |
.59 |
.77 |
|
Tgfbr2 | |
AK090393 |
10 days pregnant adult female ovary and uterus cDNA, RIKEN full-length enriched library, clone:G630098D03 product:transforming growth factor, beta receptor II, full insert sequence. [AK090393] |
KLA | .98 |
.89 |
1.00 |
.96 |
.94 |
1.00 |
.92 |
| ATP | .99 |
.99 |
.90 |
.94 |
.93 |
.96 |
1.02 |
| KLA/ATP | .92 |
.96 |
.98 |
.98 |
.98 |
.95 |
1.01 |
|
Tgfbr2 | |
NM_009371 |
transforming growth factor, beta receptor II (Tgfbr2), transcript variant 1, mRNA [NM_009371] |
KLA | .55 |
.50 |
.58 |
.50 |
.52 |
.55 |
.44 |
| ATP | .98 |
.75 |
.50 |
.32 |
.41 |
.29 |
.50 |
| KLA/ATP | .59 |
.45 |
.32 |
.23 |
.31 |
.27 |
.25 |
|
Tgfbr2 | |
NM_029575 |
transforming growth factor, beta receptor II (Tgfbr2), transcript variant 2, mRNA [NM_029575] |
KLA | .95 |
.93 |
.99 |
.95 |
.88 |
1.02 |
.82 |
| ATP | .87 |
.93 |
.84 |
.84 |
.74 |
.72 |
1.00 |
| KLA/ATP | .89 |
.85 |
.83 |
.85 |
.76 |
.80 |
.79 |
|
Tnf | |
NM_013693 |
tumor necrosis factor (Tnf), mRNA [NM_013693] |
KLA | 13.35 |
12.76 |
10.71 |
9.03 |
10.64 |
7.39 |
8.32 |
| ATP | 2.01 |
2.48 |
8.27 |
19.20 |
9.72 |
4.09 |
1.49 |
| KLA/ATP | 12.72 |
15.76 |
12.73 |
17.34 |
5.10 |
3.61 |
6.07 |
|
Tnfrsf1a
| |
NM_011609 |
tumor necrosis factor receptor superfamily, member 1a (Tnfrsf1a), mRNA [NM_011609] |
KLA | 1.74 |
1.71 |
1.90 |
2.16 |
1.95 |
1.74 |
1.16 |
| ATP | .95 |
.83 |
.55 |
.41 |
.41 |
1.55 |
1.32 |
| KLA/ATP | 1.58 |
1.49 |
1.19 |
1.03 |
.98 |
2.02 |
2.10 |
|
Traf2 | |
NM_009422 |
Tnf receptor-associated factor 2 (Traf2), mRNA [NM_009422] |
KLA | 3.38 |
3.62 |
3.49 |
3.36 |
3.49 |
3.39 |
2.68 |
| ATP | .97 |
1.04 |
1.00 |
1.10 |
1.54 |
2.40 |
1.55 |
| KLA/ATP | 3.38 |
3.16 |
2.93 |
2.74 |
2.67 |
3.11 |
4.70 |
|
Traf6 | |
NM_009424 |
Tnf receptor-associated factor 6 (Traf6), mRNA [NM_009424] |
KLA | 1.19 |
1.28 |
1.34 |
1.20 |
1.23 |
1.23 |
1.28 |
| ATP | 1.06 |
1.12 |
.92 |
1.15 |
2.46 |
1.84 |
1.40 |
| KLA/ATP | 1.32 |
1.37 |
.89 |
1.16 |
1.45 |
1.49 |
1.46 |
|
Trp53 | |
NM_011640 |
transformation related protein 53 (Trp53), mRNA [NM_011640] |
KLA | 1.25 |
1.37 |
1.11 |
.86 |
.72 |
.71 |
.95 |
| ATP | 1.15 |
1.32 |
.90 |
1.85 |
1.26 |
.68 |
.70 |
| KLA/ATP | 1.66 |
1.49 |
.80 |
1.76 |
.81 |
.65 |
.74 |
|